Page last updated: 2024-08-16

ribavirin and Disease Exacerbation

ribavirin has been researched along with Disease Exacerbation in 253 studies

Research

Studies (253)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	13 (5.14)	18.2507
2000's	121 (47.83)	29.6817
2010's	118 (46.64)	24.3611
2020's	1 (0.40)	2.80

Authors

Authors	Studies
Berg, T; Boeker, KHW; Buggisch, P; C-Registry, GH; Günther, R; Hinrichsen, H; Klinker, H; Manns, MP; Mauss, S; Müller, T; Serfert, Y; Wiegand, J; Zeuzem, S	1
Avram, L; Craciun, R; Crisan, D; Crisan, N; Epure, F; Grigorescu, M; Grigorescu, MD; Leach, N; Lupsor, M; Radu, C; Suciu, A	1
Khalili, JS; Mak, NSA; Yan, Y; Zhu, H; Zhu, Y	1
Carmona-Soria, I; Caunedo-Alvarez, A; Cordero-Ruiz, P; Flores-Cucho, A; Quezada-Pacheco, RH; Rodríguez-Téllez, M; Romero-Gómez, M; Vilches-Arenas, Á	1
Carrai, P; Coppola, C; Cordone, G; Lenci, I; Lionetti, R; Martini, S; Melazzini, M; Montilla, S; Morelli, C; Pani, L; Petraglia, S; Piai, G; Pietrosi, G; Romano, A; Russo, FP; Russo, P; Tamé, M; Toniutto, P; Trotta, MP	1
Angus, PW; George, J; Gow, P; Jeffrey, G; Mason, S; McCaughan, GW; Mitchell, J; Morales, B; Parker, FC; Roberts, SK; Strasser, SI; Tallis, C; Thompson, AJ; Thwaites, PA; Wigg, A	1
Hoan, NX; Meyer, CG; Song, LH; Tong, HV; Velavan, TP	1
Abergel, A; Besch, C; Botta-Fridlund, D; Cagnot, C; Canva, V; Chevaliez, S; Coilly, A; Conti, F; D'Alteroche, L; De Ledinghen, V; Debette-Gratien, M; Diallo, A; Duclos-Vallee, JC; Dumortier, J; Duvoux, C; Fougerou-Leurent, C; Francoz, C; Habersetzer, F; Houssel-Debry, P; Jezequel, C; Kamar, N; Lebray, P; Leroy, V; Martino, VD; Montialoux, H; Moreno, C; Pageaux, GP; Perre, P; Radenne, S; Rossignol, E; Silvain, C; Tran, A; Veislinger, A	1
Chang, F; Duan, CA; Jin, X; Lu, Y	1
Chang, Y; Cho, EJ; Cho, H; Cho, YY; Hwang, SG; Kim, HY; Kim, YJ; Lee, DH; Lee, JH; Lee, JM; Lee, YB; Nam, JY; Yoon, JH; Yu, SJ	1
Bair, MJ; Chen, HL; Cheng, CH; Chu, CY; Lee, YK; Lin, IT; Wu, CH	1
Bladé, JS; Boudin, L; de Jauréguiberry, JP; Patient, M; Roméo, E; Tsitsi Nding Tsogou, P	1
Aldámiz-Echevarría, T; Bellón, JM; Berenguer, J; Carrero, A; Díez, C; Fanciulli, C; Garcia-Broncano, P; Jiménez-Sousa, MA; Medrano, LM; Miralles, P; Pérez-Latorre, L; Resino, S	1
Abdo, AA; Al-hamoudi, W; Alfaleh, A; Alfaleh, FZ; Ali, SM; Alswat, K; Bedewi, MA; El-sharkawy, M; Hadad, Q; Helmy, A; Omar, M; Shalaby, A	1
Cariti, G; Ceretto, S; Ciancio, A; Ciccone, G; Colletta, C; De Blasi, T; Giordanino, C; Grasso, A; Marenco, S; Mazzucco, D; Picciotto, A; Pirisi, M; Rizzetto, M; Sacco, M; Saracco, G; Simondi, D; Smedile, A; Smirne, C; Traverso, A	1
Asahina, Y; Enomoto, N; Hosokawa, T; Itakura, J; Izumi, N; Kakinuma, S; Kurosaki, M; Muraoka, M; Nakagawa, M; Nakanishi, H; Nishimura, T; Suzuki, Y; Takahashi, Y; Tamaki, N; Tsuchiya, K; Ueda, K; Watanabe, M; Yasui, Y	1
Beinhardt, S; Ferenci, P; Hofer, H; Rutter, K; Scherzer, TM; Stättermayer, AF; Steindl-Munda, P; Strasser, M; Trauner, M; Wrba, F	1
Del Rio Martin, J; Fiel, MI; Satapathy, SK; Schiano, TD; Vanatta, JM	1
Dultz, G; Friedrich-Rust, M; Herrmann, E; Hofmann, WP; Kronenberger, B; Sarrazin, C; Seelhof, M; Teuber, G; Vermehren, J; von Wagner, M; Welker, MW; Zeuzem, S	1
Arakawa, Y; Higuchi, T; Matsumura, H; Moriyama, M; Nakamura, H; Nirei, K; Ogawa, M; Tanaka, N	1
Blázquez-Pérez, A; Mar, J; San Miguel, R	1
Brahm, J; Torres, C; Venegas, M	1
Rakela, J; Unzueta, A	1
Galle, PR; Grambihler, A; Kittner, JM; Koch, S; Schattenberg, JM; Schuchmann, M; Thieringer, F; Weinmann, A; Weiss, NM; Wiltink, J; Zimmermann, T	1
Barreiro, P; de Mendoza, C; Fernández-Montero, JV; Labarga, P; Sánchez-Parra, C; Soriano, V; Treviño, A; Vispo, E	1
Barluenga, E; Clotet, B; Jou, A; López, JJ; Muga, R; Ojanguren, I; Planas, R; Sanmartín, R; Sanvisens, A; Tor, J; Tural, C; Videla, S	1
Ahmed, AI; Aziz, IA; Bahnasy, KA; Fathelbab, IF; Hafez, TA; Kamal, SM; Kassim, SK; Mahmoud, S; Mansour, HM	1
Kang, W; Lu, Y; Sun, Y; Tong, HI	1
Hui, DS; Memish, ZA; Zumla, A	1
Müllhaupt, B; Rampini, SK; Schaffstein, S	1
Boots, JM; de Man, R; de Vries, MA; Samijn, JP	1
Borgia, G; Buonomo, AR; Coppola, N; Gentile, I; Zappulo, E	1
Blunn, A; Chitturi, S; Farrell, G; Kaye, G; Rodrigo, K; Rodriguez-Morales, I; Shadbolt, B; Teoh, N; To, C; Wu, JY	1
Duvnjak, M; Kurelac, I; Vince, A	1
Hrstić, I; Ostojić, R	1
Aldámiz-Echevarría, T; Bellón, JM; Berenguer, J; Carrero, A; Crespo, M; Esteban, H; Galindo, MJ; González-García, J; Guardiola, JM; López-Aldeguer, J; Montes, M; Quereda, C; Santos, I; Sanz, J; Téllez, MJ; Von Wichmann, MA; Zamora, FX	1
Ahn, SH; Baatarkhuu, O; Han, KH; Jung, KS; Kim, BK; Kim, DY; Kim, SU; Moon, C; Park, JY	1
Bielsa Marsol, I; Carrascosa Carrillo, JM; Ferrándiz Foraster, C; López Escartin, D; Masnou Ridaura, H; Morillas Cunill, R; Plana Pla, A; Planas Vilà, R; Toro Montecinos, M; Vilavella Rius, M	1
Hablas, A; Hutton, DW; Kim, DD; Raouf, AA; Salama, M; Seifeldin, IA; Soliman, AS	1
Bargach, T; Chatioui, S; Elasri, F; Iferkhass, S; Khoyaali, A; Oubaaz, A; Reda, K	1
Gerlei, Z; Gervain, J; Horváth, G; Hunyady, B; Lengyel, G; Makara, M; Pár, A; Rókusz, L; Szalay, F; Telegdy, L; Tornai, I; Werling, K	1
Cerri, K; Kuwabara, H; Mahlich, J; Treur, M; Westerhout, K; Yatsuhashi, H	1
Chi, B; Li, M; Liu, DW; Wang, J; Wu, XX; Zheng, H	1
Andersson, K; Avorn, J; Brennan, T; Choudhry, NK; Krumme, AA; Matlin, OS; Najafzadeh, M; Shrank, WH	1
Hirohashi, K; Kanazawa, A; Kubo, S; Tanaka, S; Uenishi, T; Yamamoto, T	1
Assoumou, SA; Barter, DM; Freedberg, KA; Horsburgh, CR; Kim, AY; Leff, JA; Linas, BP; Morgan, JR; Pho, MT; Salomon, JA; Schackman, BR; Weinstein, MC	1
Al Marzooqi, SH; Feld, JJ	1
Afdhal, N; Arterburn, S; Brandt-Sarif, T; Brown, K; Brown, RS; Charlton, M; Denning, J; Dvory-Sobol, H; Everson, GT; Flamm, SL; Fontana, RJ; Fried, MW; Gilroy, R; Korenblat, KM; Kumar, P; Kuo, A; Kwo, P; Landis, C; McHutchison, JG; Muir, AJ; O'Leary, JG; Pang, PS; Pungpapong, S; Reddy, KR; Schiff, E; Sulkowski, MS; Teperman, L; Terrault, NA; Vargas, HE; Watt, KD	1
Athanasakis, K; Ferrante, SA; Hill, M; Kyriopoulos, II; Kyriopoulos, J; Petrakis, I; Retsa, MP	1
Ahmad, J; Bach, N; Chang, C; Chernyiak, M; Doucette, JT; Fiel, MI; Florman, SS; Grewal, P; Khaitova, V; Kim-Schluger, L; Lim, KB; Liu, L; Odin, J; Perumalswami, P; Schiano, TD; Sima, HR	1
Charlton, MR; Dhanasekaran, R; Mounajjed, T; Sanchez, W; Watt, KD; Wiesner, RH	1
Akhtar, M; Gititu, E; Jalluri, C; Ramirez, J; Wilkins, T	1
Gissel, C; Götz, G; Mahlich, J; Repp, H	1
Baba, N; Ikeda, F; Iwasaki, Y; Miyake, Y; Moritou, Y; Nagano, T; Nanba, S; Nouso, K; Ohnishi, H; Seki, H; Senoh, T; Takaguchi, K; Takaki, A; Takeuchi, Y; Yamamoto, K; Yasunaka, T	1
Algendy, D; Amin, M; Elbadry, A; Esmat, S; Fawzi, M; Foda, A; Gabal, S; Kamal, M; Naga, M; Rashed, L; Sabry, D	1
Calvaruso, V; Craxì, A	1
Hézode, C	1
Serfaty, L	1
Chang, TT; Hsieh, YH; Huang, HT; Hung, TH; Tseng, CW; Tseng, KC; Tzeng, SJ; Wu, SF	1
Goto, H; Hayashi, K; Hirai, T; Honda, T; Ishigami, M; Ishizu, Y; Kuzuya, T; Tachi, Y	1
Cammà, C; Damele, F; Marcellusi, A; Mennini, FS; Taliani, G; Viti, R	1
Gonzalez, YS; Johnson, S; Juday, T; Misurski, D; Parisé, H; Saab, S; Virabhak, S; Wang, A	1
Castelli, F; Di Filippo, E; Di Giambenedetto, S; Di Pietro, M; Fabbiani, M; Focà, E; Gagliardini, R; Gori, A; Maggiolo, F; Pan, A; Postorino, MC; Prosperi, M; Quiros Roldan, E; Saracino, A; Sighinolfi, L; Torti, C	1
Choi, JW; Hong, SH; Jang, JW; Kim, DY; Kim, I; Kim, W; Lee, D; Lee, JI; Paik, YH; Yoon, KT	1
Chang, TT; Hsieh, YH; Huang, HT; Hung, TH; Ng, KJ; Tseng, CW; Tseng, KC; Tzeng, SJ; Wu, SF	1
Bae, SH; Cho, SB; Jang, ES; Jeong, SH; Kim, IH; Kim, YS; Lee, HC; Lee, YJ; Ok, KS	1
Fortune, BE; Lim, JK; McCarty, TR; Njei, B	1
Heger, E; Inden, S; Kaiser, R; Kalaghatgi, P; Knops, E; Neumann-Fraune, M; Schübel, N; Sierra, S	1
Antosik, D; Barcińska, D; Bereszyńska, I; Januszkiewicz-Lewandowska, D; Kałużna, E; Mozer-Lisewska, I; Nowak, J; Rembowska, J; Strauss, E; Świątek-Kościelna, B; Wysocki, J	1
Albillos, A; Arenas, J; Badia, E; Baliellas, C; Blé, M; Buti, M; Calleja, JL; Carrión, JA; Castells, L; Crespo, J; de la Mata, M; Fernández Bermejo, M; Fernández Carrillo, C; Fernández, I; Fernández-Rodriguez, C; García-Samaniego, J; Granados, R; Herrero, JI; Lens, S; Llop, E; Mariño, Z; Moreno-Palomares, JJ; Moreno-Planas, JM; Pascasio, JM; Pons, C; Prieto, M; Romero, M; Salcedo, M; Salmerón, J; Turnes, J	1
Eason, J; Lipscomb, J; Nair, S	1
Bärthel, E; Habrecht, O; Kornberg, A; Küpper, B; Settmacher, U; Tannapfel, A; Thrum, K	1
Czerwionka-Szaflarska, M; Figlerowicz, M; Gronkowska, A; Kupś, J; Liberek, A; Pawłowska, J; Szaflarska-Popławska, A; Woźniakowska-Gesicka, T; Łoś-Rycharska, E	1
Bailey, KW; Furuta, Y; Gowen, BB; Hall, JO; Jung, KH; Morrey, JD; Smee, DF; Stevens, JR; Wong, MH	1
Antonini, T; Canfora, ML; Castaing, D; Delvart, V; Duclos-Vallee, JC; Roche, B; Roque-Afonso, AM; Saliba, F; Samuel, D; Sebagh, M	1
Hartwell, D; Shepherd, J	1
Pozza, R	1
Barreiro, P; Soriano, V; Tuma, P; Vispo, E	1
Abbati, G; Belussi, F; Bonetto, S; Boninsegna, S; Borghi, A; Carbonieri, A; Corradini, E; Fagiuoli, S; Fattovich, G; Felder, M; Ferrara, F; Ferrari, C; Guido, M; Massari, M; Minola, E; Orlandini, A; Pietrangelo, A; Pozzato, G; Rizzo, G; Rossi, E; Rovere, P; Sardini, C; Tagliazucchi, M; Toniutto, P; Vegetti, A; Ventura, P; Zeneroli, ML	1
Bergamaschi, D; Focaccia, R; Patzina, R; Prado, K	1
Bonkovsky, HL; Chung, RT; Di Bisceglie, AM; Everhart, JE; Everson, GT; Ghany, MG; Greenson, JK; Hoefs, JC; Kim, HY; Lee, WM; Lindsay, KL; Lok, AS; Morishima, C; Sterling, RK	1
Damian, D; Gheorghe, C; Gheorghe, L; Grigorescu, M; Iacob, R; Iacob, S; Sirli, R; Sporea, I	1
Asjø, B; Myrmel, H; Ulvestad, E	1
Berg, T; Böcker, U; Bugert, P; Gundt, J; Haas, SL; Singer, MV; Weiss, C; Witt, H	1
Szaflarska-Popławska, A; Łoś-Rycharska, E	1
Gomes, R; Lee, C; Manka, C; Reviere, R	1
Berenguer, J; Girón, JA; González-Serrano, M; Iribarren, JA; Japón, MA; López-Cortés, LF; Macías, J; Mira, JA; Miralles, P; Moreno, A; Ortega, E; Pineda, JA; Rivero, A	1
Babany, G; Canva-Delcambre, V; Deltenre, P; Deuffic-Burban, S; Dharancy, S; Lonjon-Domanec, I; Louvet, A; Mathurin, P; Roudot-Thoraval, F	1
Alaeus, A; Blom, KG; Falconer, K; Gonzalez, VD; Laursen, AL; Mørn, B; Reichard, O; Sandberg, JK; Weis, N	1
Bonkovsky, HL; Di Bisceglie, AM; Dienstag, JL; Everson, GT; Ghany, MG; Hoefs, JC; Lee, WM; Lindsay, KL; Lok, AS; Morishima, C; Naishadham, D; Shiffman, ML; Wright, EC	1
Almerighi, C; Angelico, M; Anselmo, A; De Luca, L; Lenci, I; Lionetti, R; Monaco, A; Palmieri, G; Tariciotti, L; Tisone, G	1
Bruno, S; Gane, EJ; Hadziyannis, SJ; Marcellin, P; Messinger, D; Roberts, SK; Shiffman, ML	1
Galdame, O; Jorge, A; Sordá, J	1
González Ballerga, E; Levi, D; Reggiardo, V	1
Bruix, J; Forns, X	1
Chang, HH; Chen, IM; Shih, CC; Wang, BY; Yang, AH	1
Berenguer, M; Rubin, A	1
Hunt, DR; McClune, A; Saab, S; Stone, MA; Tong, MJ	1
Gutierrez, J; Issacson, RS; Koppel, BS	1
Bonkovsky, HL; De Santo, JL; Di Bisceglie, AM; Dienstag, JL; Ghany, MG; Kim, HY; Lee, WM; Lindsay, KL; Lok, AS; Morgan, TR; Morishima, C; Shiffman, ML; Snow, KK	1
Bonkovsky, HL; Dienstag, JL; Fontana, RJ; Goodman, ZD; Lok, AS; Naishadham, D; Sterling, RK; Su, GL; Wright, EC	1
Archimandritis, AJ; Giannaris, M; Koskinas, J; Malaktari, S; Papakostas, N; Savvas, SP	1
Lerias de Almeida, PR	1
Bakulin, IG; Iakovleva, EV; Moliarenko, EV; Sharabanov, AS	1
Banner, D; Fang, Y; Farooqui, A; Huang, SS; Kelvin, AA; Kelvin, DJ; Ng, DC; Rowe, T; Rubino, S	1
Ghany, MG; Seeff, LB	1
Akıncı, E; Bayazıt, N; Bodur, H; Erbay, A; Eren, SS; Kubar, A; Öngürü, P	1
Chiba, T; Egawa, H; Haga, H; Hatano, E; Kaido, T; Marusawa, H; Miyagawa-Hayashino, A; Mori, A; Ogawa, K; Ogura, Y; Oike, F; Takada, Y; Ueda, Y; Uemoto, S; Yoshizawa, A	1
Lawson, A	1
Abd el-Meguid, M; Anany, MA; Bader el-Din, NG; Barakat, A; el-Awady, MK; el-Zayady, AR; Esmat, G; Helmy, A; Tabll, AA; Zayed, N	1
Alter, HJ; Haynes-Williams, V; Heller, T; Herrine, SK; Hoofnagle, JH; Liang, TJ; Loomba, R; McBurney, R; Park, Y; Rehermann, B; Rivera, MM	1
Fukuda, K; Haruna, Y; Hayashi, N; Hiramatsu, N; Hosui, A; Imai, Y; Inoue, A; Inoue, Y; Kanto, T; Kasahara, A; Kiso, S; Mita, E; Miyagi, T; Mochizuki, K; Oze, T; Takehara, T; Tatsumi, T; Yakushijin, T; Yoshida, Y	1
Fujise, K; Namiki, Y; Tada, N; Tsubota, A	1
De Vincentiis, L; Durante-Mangoni, E; Iossa, D; Pinto, D; Ragone, E; Utili, R	1
Grotzinger, K; Poordad, F; Sullivan, J; Theodore, D	1
Bonkovsky, HL; Di Bisceglie, AM; Dienstag, JL; Fontana, RJ; Ghany, MG; Lee, WM; Morgan, TR; Morishima, C; Seeff, LB; Shiffman, ML; Snow, KK; Stoddard, AM; Wright, EC	1
Abdullah, NA; Amr, KS; El-Batae, HE; Elhosary, YA; Ezzat, WM; Raslan, HM	1
Masarone, M; Persico, M	1
Hiramatsu, N; Iwasaki, M; Izumi, N; Kakinnuma, S; Kurosaki, M; Matsuura, K; Sakamoto, M; Sakamoto, N; Sugauchi, F; Suzuki, Y; Tamori, A	1
Dienstag, JL; Goodman, ZD; Hoefs, JC; Kleiner, DE; Shiffman, ML; Stoddard, AM	1
Aghemo, A; Colombo, M; D'Ambrosio, R; de Franchis, R; De Nicola, S; Dell'Era, A; Donato, MF; Lampertico, P; Prati, GM; Primignani, M; Rumi, MG	1
Desenclos, JC; Deuffic-Burban, S; Dhumeaux, D; Larsen, C; Mathurin, P; Pol, S; Roudot-Thoraval, F; Yazdanpanah, Y	1
Bonkovsky, HL; Dienstag, JL; Fontana, RJ; Litman, HJ; Lok, AS; Sterling, RK; Su, G	1
Kim, R; McEwan, P; Townsend, R; Yuan, Y	1
Roche, B; Samuel, D	1
Chien, CH; Chien, RN; Hu, CC; Kuo, YL; Lin, CL; Lin, CY; Tien, HC; Weng, CH; Yen, CL	1
Ceauşu, E; Gheorghe, L; Iliescu, L; Mateescu, B; Micu, L; Mocan, T; Pascu, O; Seicean, A; Voiculescu, M	1
Cipriano, LE; Goldhaber-Fiebert, JD; Holodniy, M; Liu, S; Owens, DK	1
Alberti, AB; Belli, LS; Burra, P; Burroughs, AK; Cillo, U; De Carlis, L; De Martin, E; Fagiuoli, S; Graziadei, I; Gridelli, B; Guido, M; Lerut, J; Pasulo, L; Pinzello, G; Starkel, P; Vogel, W; Volpes, R	1
Ford, JA; Greanya, E; Partovi, N; Wilby, KJ; Yoshida, EM	1
Naggie, S; Sulkowski, MS	1
Avery, R; Budev, M; Danziger-Isakov, L; Li, L; Mossad, S	1
Di Bisceglie, AM; Dienstag, JL; Everson, GT; Ghany, MG; Lindsay, KL; Lok, AS; Morgan, TR; Morishima, C; Naishadham, D; Shiffman, ML; Szabo, G; Wright, EC	1
El Saadany, S; Enaba, M; Ghazy, M; Hasan, A; Ziada, DH	1
Andreone, P; Bertuzzo, VR; Cescon, M; Cucchetti, A; D'Errico-Grigioni, A; Dazzi, A; Del Gaudio, M; Di Gioia, P; Ercolani, G; Lorenzini, S; Morelli, MC; Pinna, AD; Ravaioli, M; Tamè, M	1
Buti, M; Deltenre, P; Deuffic-Burban, S; Hatzakis, A; Mathurin, P; Moreno, C; Mühlberger, N; Parkes, J; Rosenberg, W; Siebert, U; Stroffolini, T; Zeuzem, S	1
Bahra, M; Boas-Knoop, S; Eurich, D; Kiessling, A; Neuhaus, P; Neuhaus, R; Neumann, UP; Puhl, G; Trautwein, C; Wasmuth, H; Yahyazadeh, A	1
Chuang, WL; Dai, CY; Huang, JF; Yu, ML	1
Cai, W; Fu, Y; Guo, P; Hu, F; Qin, A; Tang, X; Xu, M; Yan, D; Yang, Q; Zhou, J	1
Karatapanis, S; Lisgos, P; Papastergiou, V; Prodromidou, K; Pselas, C; Stampori, M	1
García-Samaniego, J; González-Lahoz, J; Núñez, M; Pérez-Olmeda, M; Ríos, P; Soriano, V	1
Delahooke, TE; Hayes, PC; Kilpatrick, DC; Koch, C; Turner, ML	1
Panitch, HB	1
Blazek, J; Eason, J; Khan, S; Lipscomb, J; Loss, G; Mason, A; Nair, S	1
Grangé, JD	1
Avendano, M; Booth, CM; Cescon, DW; Chenkin, JS; Derkach, P; Detsky, AS; Dwosh, HA; Ephtimios, IE; Gold, WL; Hawryluck, LA; Kitai, I; Matukas, LM; Mazzulli, T; Mederski, BD; Poutanen, SM; Rachlis, AR; Rea, E; Rose, DB; Shadowitz, SB; Tomlinson, GA; Walmsley, SL	1
Hara, S; Hayashi, N; Hoshino, Y; Hosoya, M; Kajita, Y; Kimura, H; Morisima, T; Nakayama, T; Negoro, T; Okumura, A; Sakuma, T; Tomoda, A	1
Goldie, SJ; Hammitt, JK; Salomon, JA; Weinstein, MC	1
Levenson, D	1
Banks, A; Castro, O; Giday, S; Hasan, S; Hassan, M; Smoot, D	1
Duncan, M; Younossi, Z	1
Braun, M; Vierling, JM	1
Davis, GL	1
Busuttil, RW; Saab, S	1
Copley, L	1
Lai, CL; Poynard, T; Ratziu, V; Yuen, MF	1
Akbayram, S; Ataş, B; Caksen, H; Odabaş, D; Tepebaşili, I	1
Parini, S	1
Beersma, MF; Bredius, RG; Claas, EC; Heemskerk, B; Kroes, AC; Lankester, AC; Schilham, MW; van Tol, MJ	1
Bernstein, DE; Cheinquer, H; Cooksley, G; Craxi, A; Foster, GR; Green, J; Hassanein, TI; Jensen, DM; Klaskala, W; Lee, SS; Patel, KK; Pettit, K; Sullivan, SD	1
Pearlman, BL	1
Charlton, M; Wiesner, R	1
Yamada, G	1
Teruya, K	1
Apollonio, L; Avellini, C; Caldato, M; Fabris, C; Fumo, E; Mariuzzi, L; Minisini, R; Pirisi, M; Toniutto, P	1
Anselmi, E; Arcaini, L; Arcari, AL; Bernuzzi, P; Bertè, R; Callea, V; Cavanna, L; Lazzarino, M; Lazzaro, A; Marasca, R; Moroni, C; Sacchi, S; Trabacchi, E; Vallisa, D	1
Alberti, A	1
Molleston, JP; Rao, GS	1
Afdhal, N; Kelleher, TB	1
Blanco, JL; Forns, X; García, F; Gatell, JM; Laguno, M; Larrousse, M; León, A; Loncá, M; Mallolas, J; Martínez, E; Milinkovic, A; Miró, JM; Murillas, J; Sánchez-Tapias, JM	1
Karpov, SIu; Krel', PE	1
Jabłonowska, E	1
Bassendine, M; DeAngelis, D; Grieve, R; Main, J; Roberts, J; Rosenberg, W; Sweeting, M; Thomas, H; Wright, M	1
Alvarez Delgado, A; Fuertes Martín, A; Pérez García, ML	1
Chang, WY; Chuang, WL; Dai, CY; Yu, ML	1
Tien, PC	1
Garcia-Samaniego, J; Maida, I; Martin-Carbonero, L; Nuñez, M; Soriano, V	1
Brunner, H; Datz, C; Ferenci, P; Formann, E; Gangl, A; Gschwantler, M; Hackl, F; Hubmann, R; Kessler, HH; Klingler, A; Laferl, H; Stauber, R; Steindl-Munda, P	1
Ostojić, R	1
Bankuti, C; Donnerer, J; Grahovac, M; Kessler, HH; Stadlbauer, V; Stauber, RE; Stelzl, E	1
Blotner, S; Diago, M; Farci, P; Gane, E; Lardelli, P; O'Brien, CB; Pockros, P; Prati, D; Rajender Reddy, K; Shiffman, ML; Zeuzem, S	1
Dieterich, DT; Park, JS; Saraf, N	1
Atripaldi, L; Bellopede, P; Conca, P; Patarino, T; Perrella, A; Perrella, O; Ruggiero, L; Sbreglia, C; Sorrentino, P; Tarantino, G	1
Lawson, A; Ryder, SD	1
Bilusic, M; Hrstic, I; Huic, D; Vucelic, B	1
Ruiz-Sancho, A; Soriano, V	1
Bräu, N; Dieterich, DT; Green, J; Hornberger, J; Patel, K; Sulkowski, MS; Torres, MR; Torriani, FJ	1
Bejarano, PA; Casanova-Romero, PY; Martinez, EJ; Mindikoglu, AL; Regev, A; Schiff, ER; Tzakis, AG	1
Chen, CH; Eng, HL; Hu, TH; Hung, CH; Kuo, FY; Lee, CM; Lu, SN; Wang, JH	1
Bärthel, E; Kornberg, A; Küpper, B; Settmacher, U; Tannapfel, A; Thrum, K	1
Burioni, R; Carletti, S; Clementi, M; Craxì, A; Craxì, RD; Mancini, N; Perotti, M; Romanò, L; Zanetti, AR	1
Arora, N; Goyal, A; Kumar, GT; Sarin, SK; Shukla, DK; Suneetha, PV	1
Andrade, Z; Codes, L; Cruz, M; de Freitas, LA; Paraná, R; Schinoni, MI; Trepo, C	1
Hagiwara, H; Haruna, Y; Hayashi, N; Hijioka, T; Hiramatsu, N; Ishibashi, K; Kanto, T; Kasahara, A; Katayama, K; Kato, M; Kubota, S; Kurashige, N; Mita, E; Oshita, M; Oze, T; Takehara, T; Tamura, S; Tsuda, N; Yakushijin, T; Yoshihara, H	1
Blum, HE; Moradpour, D	1
Boix-Martínez, V; Clemente-Ricote, G; Marco-Mouriño, A; Núñez-Martínez, O; Portilla-Sogorb, J; Reus-Bañuls, S; Saiz de la Hoya-Zamácola, P; Teixidó i Pérez, N	1
Asselah, T; Belghiti, J; Boudjema, H; Durand, F; Francoz, C; Marcellin, P; Sobesky, R; Valla, D	1
Back-Madruga, C; Bonkovsky, HL; Di Bisceglie, AM; Dienstag, JL; Fontana, RJ; Ghany, MG; Gretch, DR; Kulig, CC; Malet, PF; Morgan, TR; Snow, KK; Sterling, RK	1
Addario, L; Ascione, A; Calise, F; Cuomo, O; De Luca, M; Di Costanzo, GG; Lampasi, F; Lanza, AG; Marsilia, GM; Picciotto, FP; Tartaglione, MT; Tritto, G	1
Aikaterini, T; Barbara, M; Claudio, I; Daniela, C; Danila, C; Davide, P; Gaetano, B; Giuseppe, A; Luca, I; Luciano, C; Massimo, L; Salvatore, T; Sergio, N; Stefano, C	1
Alves de Mattos, A; Ferrari de Oliveira Rigo, J; Galperim, B; Lerias de Almeida, PR; Ribeiro de Souza, A; Riegel Santos, B; Valle Tovo, C	1
Korochkina, OV; Sobchak, DM; Sobolevskaia, OL	1
Bonkovsky, HL; Chung, RT; Di Bisceglie, AM; Everhart, JE; Everson, GT; Ghany, MG; Greenson, JK; Lee, WM; Lindsay, KL; Lok, AS; Morgan, TR; Morishima, C; Padmanabhan, L; Shiffman, ML	1
Bahra, M; Berg, T; Jacob, D; Langrehr, JM; Neuhaus, P; Neuhaus, R; Neumann, UP	1
Franchini, M	1
Mátyus, J; Tornai, I	1
Duggan, AE; Duggan, JM	1
Assy, N; Embon, O	1
Asselah, T; Boyer, N; Marcellin, P; Martinot, M; Ripault, MP	1
Bosch, J; Bruguera, M; Carrión, JA; Crespo, G; Forns, X; García-Pagan, JC; García-Retortillo, M; Navasa, M	1
Danehower, S; Ghany, MG; Hoofnagle, JH; Liang, TJ; Lutchman, G; Song, BC; Thomson, M	1
Benhamou, Y; Sulkowski, MS	1
Arraes, LC; Crovella, S; Montenegro de Melo, F; Moura, P; Santos Silva, B; Segat, L; Silva Vasconcelos, LR	1
Lunel-Fabiani, F	1
Hollander, A; Jönsson, B; Lidgren, M; Weiland, O	1
Agarwal, K; Emre, S; Fiel, MI; Kontorinis, N; Schiano, TD; Stanca, CM	1
Berkan, E; Jozefowicz-Korczynska, M; Piekarska, A; Wojcik, K	1
Akazawa, K; Aoyagi, Y; Kobayashi, K; Nakamura, J; Toyabe, S	1
Alagna, L; De Bona, A; Galli, L; Gallotta, G; Guzzo, A; Lazzarin, A; Uberti-Foppa, C	1
Lengyel, G; Tulassay, Z	1
Bassett, ML	1
Adachi, Y; Araki, J; Fujita, N; Horiike, S; Iwasa, M; Kaito, M; Kobayashi, Y; Mifuji, R; Sugimoto, R; Tanaka, H; Urawa, N; Yamamoto, M	1
Buzatu, E; Cooper, CL; Dudas, J; Esguerra, R; Gorrell, MD; Haber, PS; Hilzenrat, N; Ionescu, C; Leo, MA; Lieber, CS; McCaughan, GW; Neuman, MG; Ramadori, G; Saile, B; Seth, D; Sha, K; Voiculescu, M; Winkler, RE; Wyse, J; Zakhari, S	1
Afdhal, NH; Brinkley, SC; de Oca, RM; Higgins, Y; Mehta, SH; Moore, RD; Sulkowski, MS; Thomas, DL; Torbenson, MS	1
Alvarez, E; Bellón, JM; Berenguer, J; Castillo, I; Cosín, J; López, JC; Miralles, P; Padilla, B; Resino, S; Sánchez Conde, M	1
Bani-Sadr, F; Bedossa, P; Cacoub, P; Carrat, F; De Boever, CM; Halfon, P; Lapidus, N; Perronne, C; Pol, S	1
Najm, W	1
Sharara, AI	1
Brown, JL	1
Delwaide, J	1
Pol, S; Zylberberg, H	1
Wright, TL	1
Patrick, L	1
Barnes, E; Dusheiko, G; Jacobs, R; Webster, G	1
Bjøro, K; Frøland, SS; Haaland, T; Skaug, K	1
Lawrence, SP	1
Dieterich, DT	1
Benhamou, Y; Poynard, T; Ratziu, V; Regimbeau, C	1
Albrecht, J; Bedossa, P; Davis, GL; Esteban-Mur, R; Goodman, Z; McHutchison, J; Poynard, T	1
Bastani, B; Philipneri, M	1
Berk, BS; Chou, S; Corless, CL; Gopal, DV; Olyaei, A; Orloff, SL; Rabkin, JM; Rosen, HR	1
Agarwal, K; Bassendine, DR; Bassendine, MF; Burt, AD; Craig, W; Gilvarry, E; Hewett, M; Jowett, SL; Smith, BC	1
Dieterich, D	1
Norton, M	1
Sulkowski, MS	1
Seeff, LB; Strader, DB	1
Lauer, GM; Walker, BD	1
Anderlini, P; Champlin, RE; Ghosh, S; Jacobson, K; Kontoyiannis, D; Luna, M; Raad, I; Rolston, K; Tarrand, J; Ueno, NT; Whimbey, E	1
Ramrakhiani, S; Sponseller, CA	1
Esteban, JI; Juárez, A; Sauleda, S	1

Reviews

79 review(s) available for ribavirin and Disease Exacerbation

Article	Year
Novel coronavirus treatment with ribavirin: Groundwork for an evaluation concerning COVID-19. Journal of medical virology, 2020, Volume: 92, Issue:7 Topics: Antiviral Agents; Betacoronavirus; Clinical Trials as Topic; Coronavirus Infections; COVID-19; Disease Progression; Drug Administration Schedule; Gene Expression Regulation, Viral; Humans; Pandemics; Pneumonia, Viral; Ribavirin; RNA, Viral; SARS-CoV-2; Signal Transduction	2020
Vitamin D deficiency and hepatitis viruses-associated liver diseases: A literature review. World journal of gastroenterology, 2018, Jan-28, Volume: 24, Issue:4 Topics: Antiviral Agents; Disease Progression; Drug Therapy, Combination; Hepacivirus; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferons; Ribavirin; Sustained Virologic Response; Viral Load; Vitamin D; Vitamin D Deficiency	2018
Hepatitis E infection in liver transplant recipients. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2014, Volume: 20, Issue:1 Topics: Animals; Chronic Disease; Disease Progression; Feces; Fibrosis; Food Microbiology; Hepatitis E; Humans; Immunosuppression Therapy; Interferons; Liver; Liver Failure; Liver Transplantation; Ribavirin; RNA, Viral	2014
Hepatitis C virus infection in patients with HIV-1: epidemiology, natural history and management. Expert review of gastroenterology & hepatology, 2014, Volume: 8, Issue:3 Topics: Anti-Retroviral Agents; Comorbidity; Disease Management; Disease Progression; End Stage Liver Disease; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Interferon-alpha; Liver Transplantation; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome	2014
Severe acute respiratory syndrome vs. the Middle East respiratory syndrome. Current opinion in pulmonary medicine, 2014, Volume: 20, Issue:3 Topics: Age Distribution; Animals; Antiviral Agents; Camelus; Chiroptera; Coronavirus; Coronavirus Infections; Cross Infection; Diagnosis, Differential; Disease Progression; Female; Humans; Immunity, Innate; Infectious Disease Incubation Period; Interferons; Lung; Male; Middle East; Mycophenolic Acid; Public Health; Radiography; Real-Time Polymerase Chain Reaction; Ribavirin; Severe Acute Respiratory Syndrome; Sex Distribution; Viral Load	2014
[Therapy of chronic hepatitis C]. Praxis, 2014, Apr-09, Volume: 103, Issue:8 Topics: Adult; Algorithms; Antiviral Agents; Disease Progression; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Liver Function Tests; Male; Polyethylene Glycols; Prognosis; Protease Inhibitors; Recombinant Proteins; Ribavirin	2014
Investigational nucleoside and nucleotide polymerase inhibitors and their use in treating hepatitis C virus. Expert opinion on investigational drugs, 2014, Volume: 23, Issue:9 Topics: Animals; Antiviral Agents; Disease Progression; Drug Design; Drug Therapy, Combination; Enzyme Inhibitors; Hepacivirus; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir; Uridine Monophosphate	2014
[Treatment guidelines for patients with genotype 1 chronic hepatitis C infection]. Acta medica Croatica : casopis Hravatske akademije medicinskih znanosti, 2013, Volume: 67, Issue:4 Topics: Adult; Antiviral Agents; Croatia; Disease Progression; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; National Health Programs; Polyethylene Glycols; Practice Guidelines as Topic; Recombinant Proteins; Ribavirin	2013
[Treatment of non-1 genotype chronic hepatitis C patients]. Acta medica Croatica : casopis Hravatske akademije medicinskih znanosti, 2013, Volume: 67, Issue:4 Topics: Adult; Age Factors; Antiviral Agents; Croatia; Disease Progression; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; National Health Programs; Polyethylene Glycols; Practice Guidelines as Topic; Recombinant Proteins; Ribavirin	2013
[Bilateral non-arteritic ischemic optic neuropathy during treatment of viral hepatitis C with pegylated interferon and Ribavirin]. Journal francais d'ophtalmologie, 2015, Volume: 38, Issue:1 Topics: Antiviral Agents; Disease Progression; Drug Therapy, Combination; Fluorescein Angiography; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Optic Atrophy; Optic Neuropathy, Ischemic; Papilledema; Polyethylene Glycols; Radiography; Ribavirin	2015
[Hepatitis C: diagnosis, anti-viral therapy, after-care. Hungarian consensus guideline]. Orvosi hetilap, 2015, Mar-01, Volume: 156, Issue:9 Topics: Antiviral Agents; Consensus; Disease Progression; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Hepatitis C; Humans; Hungary; Insurance Coverage; Insurance, Health; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Failure; Liver Neoplasms; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Registries; Ribavirin; Treatment Outcome	2015
IL28B rs12980275 variant as a predictor of sustained virologic response to pegylated-interferon and ribavirin in chronic hepatitis C patients: A systematic review and meta-analysis. Clinics and research in hepatology and gastroenterology, 2015, Volume: 39, Issue:5 Topics: Antiviral Agents; Biomarkers; Disease Progression; Drug Therapy, Combination; Gene Expression Regulation; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Polyethylene Glycols; Polymorphism, Single Nucleotide; Predictive Value of Tests; Recombinant Proteins; Ribavirin; Sensitivity and Specificity; Treatment Outcome; Viral Load	2015
Sorting out cirrhosis: mechanisms of non-response to hepatitis C therapy. Liver international : official journal of the International Association for the Study of the Liver, 2015, Volume: 35, Issue:8 Topics: Antiviral Agents; Disease Progression; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Prognosis; Ribavirin; Risk Assessment; Survival Analysis; Treatment Failure	2015
Diagnosis and Management of Hepatitis C. American family physician, 2015, Jun-15, Volume: 91, Issue:12 Topics: Antiviral Agents; Disease Progression; Genotype; Hepacivirus; Hepatitis Antibodies; Hepatitis C; Humans; Interferon-alpha; Liver Diseases; Mass Screening; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Factors; RNA, Viral; Severity of Illness Index; Viral Load; Viral Nonstructural Proteins	2015
Why do I treat my patients with mild hepatitis C? Liver international : official journal of the International Association for the Study of the Liver, 2016, Volume: 36 Suppl 1 Topics: Antiviral Agents; Cost-Benefit Analysis; Disease Progression; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Ribavirin; Treatment Outcome	2016
Why I do not treat patients for mild disease. Liver international : official journal of the International Association for the Study of the Liver, 2016, Volume: 36 Suppl 1 Topics: Antiviral Agents; Cost-Benefit Analysis; Disease Progression; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Ribavirin	2016
Follow-up of patients with chronic hepatitis C and a sustained viral response. Liver international : official journal of the International Association for the Study of the Liver, 2016, Volume: 36 Suppl 1 Topics: Antiviral Agents; Biomarkers; Carcinoma, Hepatocellular; Comorbidity; Disease Progression; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Liver Cirrhosis; Liver Neoplasms; Polyethylene Glycols; Ribavirin; Risk Factors; RNA, Viral; Treatment Outcome	2016
Pegylated and non-pegylated interferon-alfa and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and meta-analysis. International journal of technology assessment in health care, 2009, Volume: 25, Issue:1 Topics: Antiviral Agents; Disease Progression; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Severity of Illness Index; Treatment Outcome	2009
Clinical management of HIV/hepatitis C virus coinfection. Journal of the American Academy of Nurse Practitioners, 2008, Volume: 20, Issue:10 Topics: Antiretroviral Therapy, Highly Active; Antiviral Agents; Comorbidity; Disease Progression; Drug Monitoring; Drug Therapy, Combination; Health Services Needs and Demand; Hepatitis C; HIV Infections; Humans; Interferons; Liver Cirrhosis; Medication Adherence; Nurse Practitioners; Nurse's Role; Ribavirin; Risk Factors; Severity of Illness Index; Social Support	2008
[Role of tenofovir in HIV and hepatitis C virus coinfection]. Enfermedades infecciosas y microbiologia clinica, 2008, Volume: 26 Suppl 8 Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Chemical and Drug Induced Liver Injury; Disease Progression; Drug Hypersensitivity; Drug Interactions; Drug Therapy, Combination; Fatty Liver; Glucose Metabolism Disorders; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Liver; Liver Cirrhosis; Organophosphonates; Reverse Transcriptase Inhibitors; Ribavirin; Tenofovir	2008
The hepatitis C virus enigma. APMIS : acta pathologica, microbiologica, et immunologica Scandinavica, 2009, Volume: 117, Issue:5-6 Topics: Antigens, CD; Antiviral Agents; Biological Evolution; Disease Progression; Drug Synergism; Hepacivirus; Hepatitis C, Chronic; Host-Pathogen Interactions; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Polyethylene Glycols; Receptors, Virus; Recombinant Proteins; Ribavirin; T-Lymphocyte Subsets; Tetraspanin 28; Viral Hepatitis Vaccines; Viremia; Virus Replication	2009
Influence of selected HLA tissue compatibility antigens on the course and efficacy of viral hepatitis C treatment--actual knowledge position. Advances in medical sciences, 2009, Volume: 54, Issue:1 Topics: Antiviral Agents; Disease Progression; Drug Therapy, Combination; Evidence-Based Practice; Haplotypes; Hepacivirus; Hepatitis C; HLA Antigens; Humans; Interferons; Major Histocompatibility Complex; Ribavirin; Treatment Outcome	2009
Treatment options for hepatitis C and the rationale for low response rates in African Americans. Journal of the National Medical Association, 2009, Volume: 101, Issue:6 Topics: Antiviral Agents; Black or African American; Disease Progression; Hepatitis C, Chronic; Humans; Immunologic Factors; Interferon-alpha; Ribavirin; Treatment Outcome; United States; White People	2009
Subacute sclerosing panencephalitis: an update. Developmental medicine and child neurology, 2010, Volume: 52, Issue:10 Topics: Antibodies, Viral; Antiviral Agents; Apoptosis; Brain; Demyelinating Diseases; Disease Progression; Drug Therapy, Combination; Electroencephalography; Epilepsies, Myoclonic; Female; Gliosis; Humans; Inosine Pranobex; Interferon-alpha; Magnetic Resonance Imaging; Male; Measles; Measles Vaccine; Measles virus; Ribavirin; Severity of Illness Index; Sex Factors; Subacute Sclerosing Panencephalitis; Time Factors; Virion	2010
Acute hepatitis C treatment. Annals of hepatology, 2010, Volume: 9 Suppl Topics: Acute Disease; Antiviral Agents; Disease Progression; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis C; Humans; Interferon-alpha; Patient Selection; Ribavirin; Treatment Outcome	2010
[Thrombocytopenia in patients with chronic hepatitis C]. Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology, 2010, Issue:5 Topics: Antiviral Agents; Biomarkers; Disease Progression; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Thrombocytopenia	2010
Management of untreated and nonresponder patients with chronic hepatitis C. Seminars in liver disease, 2010, Volume: 30, Issue:4 Topics: Alcohol Drinking; Antiviral Agents; Biopsy; Decision Making; Deoxycytidine; Disease Management; Disease Progression; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Liver Function Tests; Male; Middle Aged; Obesity; Polyethylene Glycols; Practice Patterns, Physicians'; Recombinant Proteins; Retreatment; Ribavirin; RNA, Viral; Treatment Failure; Viral Load; Virus Replication	2010
Peginterferon and ribavirin treatment for hepatitis C virus infection. World journal of gastroenterology, 2011, Jan-28, Volume: 17, Issue:4 Topics: Antiviral Agents; Disease Progression; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome	2011
Antiviral therapy: why does it fail in HCV-related chronic hepatitis? Expert review of anti-infective therapy, 2011, Volume: 9, Issue:5 Topics: Antiviral Agents; Carcinoma, Hepatocellular; Clinical Trials as Topic; Cryoglobulinemia; Disease Progression; Drug Resistance, Viral; Female; Glomerulonephritis; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Lymphoma, Non-Hodgkin; Male; Ribavirin; RNA, Viral; Sex Factors; Treatment Outcome; Viral Load	2011
Structural frameworks and key model parameters in cost-effectiveness analyses for current and future treatments of chronic hepatitis C. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 2011, Volume: 14, Issue:8 Topics: Antiviral Agents; Cost-Benefit Analysis; Disease Progression; Drug Costs; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferons; Models, Economic; Quality-Adjusted Life Years; Ribavirin	2011
Hepatitis C virus treatment pre- and post-liver transplantation. Liver international : official journal of the International Association for the Study of the Liver, 2012, Volume: 32 Suppl 1 Topics: Antiviral Agents; Disease Progression; Drug Administration Schedule; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Oligopeptides; Polyethylene Glycols; Postoperative Complications; Proline; Recombinant Proteins; Recurrence; Ribavirin; Serine Proteinase Inhibitors; Time Factors; Viral Load	2012
Review of boceprevir and telaprevir for the treatment of chronic hepatitis C. Canadian journal of gastroenterology = Journal canadien de gastroenterologie, 2012, Volume: 26, Issue:4 Topics: Antiviral Agents; Disease Management; Disease Progression; Drug Interactions; Drug Therapy, Combination; Genome, Viral; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Standard of Care; Treatment Outcome; Viral Load	2012
Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals. Gastroenterology, 2012, Volume: 142, Issue:6 Topics: Adenine; Anti-HIV Agents; Antiviral Agents; Coinfection; Deoxycytidine; Dideoxynucleosides; Disease Progression; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Emtricitabine; Hepatitis C, Chronic; HIV Infections; Homosexuality, Male; Humans; Interferon-alpha; Lamivudine; Liver Cirrhosis; Liver Diseases; Male; Oligopeptides; Organophosphonates; Polyethylene Glycols; Proline; Pyrrolidinones; Raltegravir Potassium; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; Substance Abuse, Intravenous; Tenofovir; Treatment Outcome	2012
Glucose abnormalities in hepatitis C virus infection. The Kaohsiung journal of medical sciences, 2013, Volume: 29, Issue:2 Topics: Adult; Antiviral Agents; Diabetes Mellitus, Type 2; Disease Progression; Female; Glucose; Hepacivirus; Hepatitis C, Chronic; Humans; Insulin; Insulin Resistance; Interferon-alpha; Male; Middle Aged; Ribavirin	2013
Respiratory syncytial virus bronchiolitis: supportive care and therapies designed to overcome airway obstruction. The Pediatric infectious disease journal, 2003, Volume: 22, Issue:2 Suppl Topics: Airway Obstruction; Antiviral Agents; Bronchiolitis, Viral; Bronchodilator Agents; Child; Child, Preschool; Disease Progression; Fluid Therapy; Humans; Infant; Infant, Newborn; Oxygen Inhalation Therapy; Respiratory Syncytial Virus Infections; Respiratory Syncytial Virus, Human; Ribavirin; Risk Factors; Severity of Illness Index; Virus Replication	2003
[Screening and treatment of acute hepatitis C]. Gastroenterologie clinique et biologique, 2003, Volume: 27, Issue:3 Pt 1 Topics: Acute Disease; Antiviral Agents; Disease Progression; Drug Administration Schedule; Hepatitis C; Humans; Interferon-alpha; Mass Screening; Ribavirin; Risk Factors; Treatment Outcome	2003
HCV in sickle cell disease. Journal of the National Medical Association, 2003, Volume: 95, Issue:9 Topics: Anemia, Sickle Cell; Antiviral Agents; Chronic Disease; Comorbidity; Disease Progression; Genotype; Hepacivirus; Hepatitis C; Humans; Interferons; Liver; Prevalence; Ribavirin; Transfusion Reaction; United States	2003
Treatment options for nonresponders and relapsers to initial therapy for hepatitis C. Cleveland Clinic journal of medicine, 2003, Volume: 70 Suppl 4 Topics: Antiviral Agents; Carcinoma, Hepatocellular; Disease Progression; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver Neoplasms; Recurrence; Retreatment; Ribavirin	2003
The clinical and immunologic impact of using interferon and ribavirin in the immunosuppressed host. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2003, Volume: 9, Issue:11 Topics: Adjuvants, Immunologic; Antiviral Agents; Disease Progression; Drug Therapy, Combination; Humans; Immunosuppressive Agents; Interferon-alpha; Liver; Muromonab-CD3; Ribavirin; Transplantation, Homologous	2003
New approaches and therapeutic modalities for the prevention and treatment of recurrent HCV after liver transplantation. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2003, Volume: 9, Issue:11 Topics: Animals; Antiviral Agents; Disease Progression; Hepacivirus; Hepatitis C; Humans; Liver Cirrhosis; Liver Transplantation; Ribavirin; RNA, Viral; Secondary Prevention; Virus Replication	2003
Practical management of liver transplant recipients for hepatitis C. Minerva chirurgica, 2003, Volume: 58, Issue:4 Topics: Antiviral Agents; Combined Modality Therapy; Disease Progression; Hepacivirus; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Recurrence; Reoperation; Ribavirin; Treatment Outcome	2003
Viral hepatitis C. Lancet (London, England), 2003, Dec-20, Volume: 362, Issue:9401 Topics: Adult; Antiviral Agents; Comorbidity; Disease Progression; Enzyme-Linked Immunosorbent Assay; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Serotyping; Severity of Illness Index	2003
Hepatitis C treatment update. The American journal of medicine, 2004, Sep-01, Volume: 117, Issue:5 Topics: Acute Disease; Adjuvants, Immunologic; Algorithms; Antiviral Agents; Chronic Disease; Decision Trees; Disease Progression; Drug Monitoring; Drug Therapy, Combination; Forecasting; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Patient Compliance; Polyethylene Glycols; Prevalence; Recombinant Proteins; Ribavirin; RNA, Viral; Severity of Illness Index; Treatment Outcome; United States; Viral Load	2004
Natural history and management of hepatitis C infection after liver transplantation. Seminars in liver disease, 2004, Volume: 24 Suppl 2 Topics: Disease Progression; Hepacivirus; Hepatitis C, Chronic; Humans; Immunoglobulins; Interferon alpha-2; Interferon-alpha; Kidney Failure, Chronic; Liver Transplantation; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin	2004
[Clinical aspects of type-C cirrhosis of liver--diagnosis, clinical course, treatment and prognosis]. Nihon rinsho. Japanese journal of clinical medicine, 2004, Volume: 62 Suppl 7, Issue:Pt 1 Topics: Antiviral Agents; Carcinoma, Hepatocellular; Cysteine; Disease Progression; Drug Combinations; Drug Therapy, Combination; Fibrosis; Glycine; Hepatitis C, Chronic; Humans; Interferons; Liver; Liver Cirrhosis; Liver Neoplasms; Oleanolic Acid; Prognosis; Ribavirin; Risk; Ursodeoxycholic Acid	2004
[Hepatitis C in the HIV-infected person]. Nihon rinsho. Japanese journal of clinical medicine, 2004, Volume: 62 Suppl 7, Issue:Pt 1 Topics: Antiretroviral Therapy, Highly Active; Antiviral Agents; Chemical and Drug Induced Liver Injury; Disease Progression; Drug Interactions; Drug Therapy, Combination; Hepatitis C; HIV Infections; Humans; Interferons; Liver Transplantation; Prognosis; Ribavirin; Temperance	2004
Towards more individualised management of hepatitis C virus patients with initially or persistently normal alanineaminotransferase levels. Journal of hepatology, 2005, Volume: 42, Issue:2 Topics: Alanine Transaminase; Antiviral Agents; Disease Progression; Drug Therapy, Combination; Hepatitis C; Humans; Liver; Reference Values; Ribavirin	2005
Children with hepatitis C. Current gastroenterology reports, 2005, Volume: 7, Issue:1 Topics: Age Distribution; Antiviral Agents; Child; Child, Preschool; Disease Progression; Disease Transmission, Infectious; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Incidence; Infant; Infectious Disease Transmission, Vertical; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Male; Prognosis; Recombinant Proteins; Ribavirin; Risk Assessment; Severity of Illness Index; Sex Distribution	2005
Maintenance therapy for chronic hepatitis C. Current gastroenterology reports, 2005, Volume: 7, Issue:1 Topics: Antiviral Agents; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Function Tests; Long-Term Care; Male; Prognosis; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Risk Assessment; Severity of Illness Index; Survival Analysis; Viral Load	2005
[Advances in the diagnosis and treatment of hepatitis C virus infection in patients with and without HIV infection]. Enfermedades infecciosas y microbiologia clinica, 2005, Volume: 23, Issue:1 Topics: Abnormalities, Drug-Induced; Antiviral Agents; Biopsy; Comorbidity; Disease Progression; Female; Hematologic Diseases; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Liver; Male; Ribavirin	2005
[Clinical characterization and peculiarities of the clinical course of low-activity hepatitis C]. Klinicheskaia meditsina, 2005, Volume: 83, Issue:1 Topics: Adult; Antiviral Agents; Biopsy; Carcinoma, Hepatocellular; Clinical Trials as Topic; Disease Progression; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Prognosis; Recombinant Proteins; Ribavirin	2005
[Coinfection with HIV and HCV--epidemiologic, diagnostic, clinical and therapeutic implications]. Przeglad epidemiologiczny, 2004, Volume: 58, Issue:4 Topics: AIDS-Related Opportunistic Infections; Antiretroviral Therapy, Highly Active; Antiviral Agents; Disease Progression; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Ribavirin; Risk Factors	2004
[Treatment of chronic hepatitis C virus infection in human immunodeficiency virus (HIV) infected patients]. Anales de medicina interna (Madrid, Spain : 1984), 2005, Volume: 22, Issue:6 Topics: Antiviral Agents; Disease Progression; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Spain	2005
Treatment of chronic hepatitis C in southern Taiwan. Intervirology, 2006, Volume: 49, Issue:1-2 Topics: Antiviral Agents; Carcinoma, Hepatocellular; Clinical Trials as Topic; Disease Progression; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Neoplasms; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Species Specificity; Taiwan; Viral Load	2006
New paradigms in the management of HIV and hepatitis C virus coinfection. Current opinion in infectious diseases, 2005, Volume: 18, Issue:6 Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; Clinical Trials as Topic; Disease Progression; Drug Interactions; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Multicenter Studies as Topic; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome	2005
HBV plus HCV, HCV plus HIV, HBV plus HIV. Current gastroenterology reports, 2006, Volume: 8, Issue:1 Topics: Algorithms; Antiviral Agents; Carcinoma, Hepatocellular; Chronic Disease; Disease Progression; Drug Interactions; Hepatitis B; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Diseases; Liver Neoplasms; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Load	2006
Progression of hepatic fibrosis in chronic hepatitis C and the need for treatment in mild disease. European journal of gastroenterology & hepatology, 2006, Volume: 18, Issue:4 Topics: Adult; Aged; Antiviral Agents; Disease Progression; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Risk Factors	2006
[HIV and HCV coinfection]. Enfermedades infecciosas y microbiologia clinica, 2006, Volume: 24, Issue:5 Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Carcinoma, Hepatocellular; CD4 Lymphocyte Count; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Contraindications; Disease Progression; Drug Interactions; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Liver Cirrhosis; Liver Neoplasms; Multicenter Studies as Topic; Patient Selection; Polyethylene Glycols; Ribavirin; Risk Factors; Treatment Outcome; Viral Load	2006
[Therapy of chronic hepatitis C]. Praxis, 2006, Sep-20, Volume: 95, Issue:38 Topics: Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin	2006
[Hepatitis C and liver transplantation: fibrosis progression and treatment. Or how to improve management]. Gastroenterologie clinique et biologique, 2006, Volume: 30, Issue:11 Topics: Antiviral Agents; Disease Progression; Drug Therapy, Combination; Graft Rejection; Hepatitis C; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Liver Transplantation; Postoperative Complications; Ribavirin; Secondary Prevention; Treatment Outcome	2006
Is time to treat for HCV all the HIV/HCV co-infected hemophiliacs? Hematology (Amsterdam, Netherlands), 2006, Volume: 11, Issue:3 Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Carcinoma, Hepatocellular; Case Management; Clinical Trials as Topic; Cohort Studies; Disease Progression; Drug Therapy, Combination; Hemophilia A; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Liver Cirrhosis; Liver Failure; Liver Neoplasms; Multicenter Studies as Topic; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin	2006
[Treatment of hepatitis C in patients on renal replacement therapy]. Orvosi hetilap, 2007, Mar-18, Volume: 148, Issue:11 Topics: Antiviral Agents; Cross Infection; Disease Progression; Drug Therapy, Combination; Graft Rejection; Hepacivirus; Hepatitis C; Hepatitis C Antibodies; Humans; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Kidney Failure, Chronic; Kidney Transplantation; Liver; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Renal Dialysis; Ribavirin	2007
Management of chronic hepatitis C. Minerva gastroenterologica e dietologica, 2007, Volume: 53, Issue:1 Topics: Antiviral Agents; Decision Trees; Disease Progression; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Ribavirin	2007
Therapeutic issues in HIV/HCV-coinfected patients. Journal of viral hepatitis, 2007, Volume: 14, Issue:6 Topics: Anemia; Antiviral Agents; Chemical and Drug Induced Liver Injury; Disease Progression; Drug Therapy, Combination; Hepatitis C; HIV; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Leukopenia; Liver Cirrhosis; Liver Transplantation; Mitochondrial Diseases; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome	2007
[Treatment of recurrent hepatitis C virus infection after liver transplantation]. Orvosi hetilap, 2007, Oct-07, Volume: 148, Issue:40 Topics: Antiviral Agents; Disease Progression; Drug Therapy, Combination; Hepatitis C; Humans; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin	2007
Inflammation and repair in viral hepatitis C. Digestive diseases and sciences, 2008, Volume: 53, Issue:6 Topics: Alcoholism; Antiviral Agents; Carcinoma, Hepatocellular; Cytokines; Disease Progression; Genotype; Hepatitis C, Chronic; HIV Infections; Humans; Inflammation; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Ribavirin; Risk Factors	2008
Viral hepatitis: how to manage type C and D infections. Geriatrics, 1997, Volume: 52, Issue:5 Topics: Acute Disease; Aged; Antiviral Agents; Chronic Disease; Disease Progression; Hepatitis B; Hepatitis C; Hepatitis D; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin	1997
Chronic hepatitis C. Southern medical journal, 1997, Volume: 90, Issue:9 Topics: Antiviral Agents; Blood Transfusion; Carcinoma, Hepatocellular; Cryoglobulinemia; Disease Progression; Forecasting; Genotype; Glomerulonephritis, Membranoproliferative; Hepacivirus; Hepatitis C; Hepatitis, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Porphyria Cutanea Tarda; Ribavirin; Risk Factors; Treatment Outcome	1997
[Update on hepatitis C: potential transmission by invasive medical examinations; new therapeutic modalities (1)]. Revue medicale de Liege, 1998, Volume: 53, Issue:8 Topics: Acute Disease; Antiviral Agents; Chronic Disease; Combined Modality Therapy; Cross Infection; Disease Progression; Hepatitis C; Humans; Interferons; Ribavirin	1998
[Interactions between the human immunodeficiency virus and hepatitis C virus]. La Revue de medecine interne, 1998, Volume: 19, Issue:12 Topics: Anti-HIV Agents; Antiviral Agents; Comorbidity; Disease Progression; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Prevalence; Ribavirin; Virus Replication	1998
Hepatitis C: epidemiology and review of complementary/alternative medicine treatments. Alternative medicine review : a journal of clinical therapeutic, 1999, Volume: 4, Issue:4 Topics: Antioxidants; Antiviral Agents; Catechin; Complementary Therapies; Disease Progression; Glycyrrhizic Acid; Hepacivirus; Hepatitis C; Humans; Phytosterols; Plant Extracts; Ribavirin; Silymarin	1999
Long-term efficacy of treatment of chronic hepatitis C with alpha interferon or alpha interferon and ribavirin. Journal of hepatology, 1999, Volume: 31 Suppl 1 Topics: Antiviral Agents; Disease Progression; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin; Time Factors	1999
Advances in the treatment of hepatitis C. Advances in internal medicine, 2000, Volume: 45 Topics: Antiviral Agents; Biopsy; Clinical Protocols; Disease Progression; Drug Therapy, Combination; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon Type I; Liver Cirrhosis; Liver Failure; Ribavirin	2000
Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology (Baltimore, Md.), 2000, Volume: 32, Issue:5 Topics: Adult; Antiviral Agents; Disease Progression; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Multivariate Analysis; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin	2000
Kidney disease in patients with chronic hepatitis C. Current gastroenterology reports, 2001, Volume: 3, Issue:1 Topics: Antigen-Antibody Complex; Antiviral Agents; Disease Progression; Glomerulonephritis; Hepatitis C, Chronic; Humans; Interferon-alpha; Kidney Diseases; Kidney Transplantation; Postoperative Complications; Recurrence; Ribavirin; Treatment Outcome	2001
Hepatitis C: a brief clinical overview. ILAR journal, 2001, Volume: 42, Issue:2 Topics: Antiviral Agents; Black People; Carcinoma, Hepatocellular; Disease Progression; Drug Therapy, Combination; Hepatitis C; Humans; Interferons; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Public Health; Remission, Spontaneous; Ribavirin	2001
Hepatitis C virus infection. The New England journal of medicine, 2001, Jul-05, Volume: 345, Issue:1 Topics: Antiviral Agents; Disease Progression; Drug Therapy, Combination; Genome, Viral; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Interferon-alpha; Liver; Liver Transplantation; Prevalence; Ribavirin; Transfusion Reaction	2001
Treatment of hepatitis B and C following liver transplantation. Current gastroenterology reports, 2002, Volume: 4, Issue:1 Topics: Adenine; Antiviral Agents; Clinical Trials as Topic; Disease Progression; Drug Resistance; Drug Therapy, Combination; Hepatitis B; Hepatitis C; Humans; Immunoglobulins; Interferon-alpha; Lamivudine; Liver Transplantation; Organophosphonates; Prognosis; Ribavirin; Secondary Prevention; Survival Rate	2002
[Treatment of chronic hepatitis C in patients with HIV-coinfection]. Gastroenterologia y hepatologia, 2002, Volume: 25, Issue:5 Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Chemical and Drug Induced Liver Injury; Disease Progression; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Ribavirin	2002

Trials

28 trial(s) available for ribavirin and Disease Exacerbation

Article	Year
12 Weeks of a Ribavirin-Free Sofosbuvir and Nonstructural Protein 5A Inhibitor Regimen Is Enough to Treat Recurrence of Hepatitis C After Liver Transplantation. Hepatology (Baltimore, Md.), 2018, Volume: 68, Issue:4 Topics: Adult; Aged; Belgium; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; France; Graft Survival; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Prognosis; Prospective Studies; Recurrence; Ribavirin; Sofosbuvir; Treatment Outcome; Viral Nonstructural Proteins	2018
Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease. Gastroenterology, 2015, Volume: 149, Issue:3 Topics: Antiviral Agents; Benzimidazoles; Cholestasis, Intrahepatic; Disease Progression; Drug Combinations; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Ribavirin; Sofosbuvir; Time Factors; Treatment Outcome; United States; Uridine Monophosphate	2015
Association of hepatic oxidative stress and iron dysregulation with HCC development after interferon therapy in chronic hepatitis C. Journal of clinical pathology, 2016, Volume: 69, Issue:3 Topics: 8-Hydroxy-2'-Deoxyguanosine; Aged; Antiviral Agents; Biomarkers; Carcinoma, Hepatocellular; Deoxyguanosine; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon-alpha; Iron Metabolism Disorders; Leukocytes, Mononuclear; Liver; Liver Neoplasms; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Oxidative Stress; Polyethylene Glycols; Proportional Hazards Models; Recombinant Proteins; Ribavirin; Risk Factors; Severity of Illness Index; Time Factors; Treatment Outcome	2016
Efficacy of interferon based antiviral therapy for recurrent hepatitis C in patients who received steroid free immunosuppression for liver transplantation. Transplantation, 2008, Aug-15, Volume: 86, Issue:3 Topics: Amantadine; Antibodies, Monoclonal; Antilymphocyte Serum; Antiviral Agents; Disease Progression; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load	2008
Sustained clearance of serum hepatitis C virus-RNA independently predicts long-term survival in liver transplant patients with recurrent hepatitis C. Transplantation, 2008, Aug-15, Volume: 86, Issue:3 Topics: Adult; Aged; Antiviral Agents; Disease Progression; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Kaplan-Meier Estimate; Liver Cirrhosis; Liver Transplantation; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load	2008
Evolution of hepatic steatosis in patients with advanced hepatitis C: results from the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial. Hepatology (Baltimore, Md.), 2009, Volume: 49, Issue:6 Topics: Antiviral Agents; Disease Progression; Fatty Liver; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Time Factors	2009
Effect of HCV RNA suppression during peginterferon alfa-2a maintenance therapy on clinical outcomes in the HALT-C trial. Gastroenterology, 2009, Volume: 137, Issue:6 Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Disease Progression; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Kaplan-Meier Estimate; Liver Cirrhosis; Liver Failure; Liver Neoplasms; Male; Middle Aged; Polyethylene Glycols; Proportional Hazards Models; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Time Factors; Treatment Failure; Viral Load	2009
Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis. Hepatology (Baltimore, Md.), 2010, Volume: 51, Issue:2 Topics: Adult; Antiviral Agents; Disease Progression; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin	2010
Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology (Baltimore, Md.), 2010, Volume: 52, Issue:3 Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Disease Progression; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Neoplasms; Male; Middle Aged; Polyethylene Glycols; Prognosis; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; Risk Factors; Severity of Illness Index; Survival Rate; Treatment Outcome; United States	2010
Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C. Gut, 2010, Volume: 59, Issue:10 Topics: Adult; Biomarkers; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Models, Statistical; Polyethylene Glycols; Prognosis; Recombinant Proteins; Ribavirin	2010
Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon. Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Cause of Death; Disease Progression; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin	2011
Rate of progression of hepatic fibrosis in patients with chronic hepatitis C: results from the HALT-C Trial. Gastroenterology, 2011, Volume: 141, Issue:3 Topics: Adult; Antiviral Agents; Biopsy; Carcinoma, Hepatocellular; Disease Progression; Drug Therapy, Combination; Female; Fibrosis; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Polyethylene Glycols; Prevalence; Prognosis; Recombinant Proteins; Ribavirin; Time Factors; Treatment Outcome	2011
The course of esophageal varices in patients with hepatitis C cirrhosis responding to interferon/ribavirin therapy. Antiviral therapy, 2011, Volume: 16, Issue:5 Topics: Antiviral Agents; Disease Progression; Endoscopy, Gastrointestinal; Esophageal and Gastric Varices; Female; Gastrointestinal Hemorrhage; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Liver Cirrhosis; Liver Function Tests; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Risk; Time Factors; Treatment Outcome	2011
YKL-40 genetic polymorphisms and the risk of liver disease progression in patients with advanced fibrosis due to chronic hepatitis C. Liver international : official journal of the International Association for the Study of the Liver, 2012, Volume: 32, Issue:4 Topics: Adipokines; Adult; Chitinase-3-Like Protein 1; Disease Progression; Female; Genetic Association Studies; Genetic Predisposition to Disease; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Lectins; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Genetic; Promoter Regions, Genetic; Recombinant Proteins; Ribavirin	2012
Antiviral therapy and fibrosis progression in patients with mild-moderate hepatitis C recurrence after liver transplantation. A randomized controlled study. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2012, Volume: 44, Issue:7 Topics: Adult; Aged; Antiviral Agents; Biopsy; Chi-Square Distribution; Disease Progression; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Liver Transplantation; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Viral Load	2012
Reduction in Hepatic Inflammation Is Associated With Less Fibrosis Progression and Fewer Clinical Outcomes in Advanced Hepatitis C. The American journal of gastroenterology, 2012, Volume: 107, Issue:9 Topics: Adult; Aged; Antiviral Agents; Biopsy; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon-alpha; Kaplan-Meier Estimate; Liver; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Proportional Hazards Models; Recombinant Proteins; Ribavirin; Treatment Outcome	2012
Role of anti-hepatitis C virus (HCV) treatment in HCV-related, low-grade, B-cell, non-Hodgkin's lymphoma: a multicenter Italian experience. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Jan-20, Volume: 23, Issue:3 Topics: Adult; Aged; Antiviral Agents; Disease Progression; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Lymphoma, B-Cell; Male; Middle Aged; Polyethylene Glycols; Prognosis; Prospective Studies; Recombinant Proteins; Ribavirin; Viral Load	2005
Cost effectiveness of interferon alpha or peginterferon alpha with ribavirin for histologically mild chronic hepatitis C. Gut, 2006, Volume: 55, Issue:9 Topics: Adult; Aged; Antiviral Agents; Cost-Benefit Analysis; Disease Progression; Drug Costs; Drug Therapy, Combination; Health Care Costs; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Models, Econometric; Polyethylene Glycols; Quality of Life; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin; Severity of Illness Index; United Kingdom	2006
Randomized, double-blind, placebo-controlled study of peginterferon alfa-2a (40KD) plus ribavirin with or without amantadine in treatment-naïve patients with chronic hepatitis C genotype 1 infection. Journal of hepatology, 2006, Volume: 44, Issue:2 Topics: Adult; Amantadine; Antiviral Agents; Disease Progression; Double-Blind Method; Drug Carriers; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Quality of Life; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome	2006
Viral and metabolic factors influencing alanine aminotransferase activity in patients with chronic hepatitis C. Journal of hepatology, 2006, Volume: 44, Issue:4 Topics: Alanine Transaminase; Antiviral Agents; Blood Glucose; Blood Pressure; Body Mass Index; Disease Progression; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Linear Models; Male; Metabolic Syndrome; Metabolism; Polyethylene Glycols; Recombinant Proteins; Reference Values; Ribavirin; RNA, Viral; Sex Factors; Triglycerides	2006
Impact of steatosis on long-term histological outcome in chronic hepatitis C after antiviral therapy. Antiviral therapy, 2006, Volume: 11, Issue:4 Topics: Adult; Aged; Antiviral Agents; Biopsy; Disease Progression; Fatty Liver; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Recombinant Proteins; Ribavirin; RNA, Viral	2006
Modulation of epitope-specific anti-hepatitis C virus E2 (anti-HCV/E2) antibodies by anti-viral treatment. Journal of medical virology, 2006, Volume: 78, Issue:10 Topics: 5' Untranslated Regions; Adult; Antibody Specificity; Antiviral Agents; Disease Progression; Drug Therapy, Combination; Epitopes; Female; Hepacivirus; Hepatitis C; Hepatitis C Antibodies; Humans; Interferon-alpha; Male; Middle Aged; Molecular Conformation; Neutralization Tests; Polyethylene Glycols; Ribavirin; Time Factors; Treatment Outcome; Viral Core Proteins; Viral Envelope Proteins; Viremia	2006
Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis. Journal of hepatology, 2007, Volume: 46, Issue:3 Topics: Adult; Antiviral Agents; Disease Progression; Drug Therapy, Combination; Female; Health Status; Health Surveys; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Multivariate Analysis; Prospective Studies; Quality of Life; Recombinant Proteins; Ribavirin; Sexual Behavior; Sexual Dysfunctions, Psychological; Treatment Outcome	2007
Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation. Journal of hepatology, 2007, Volume: 46, Issue:3 Topics: Adult; Aged; Antiviral Agents; Cohort Studies; Disease Progression; Dose-Response Relationship, Drug; Female; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Secondary Prevention; Survival Rate; Treatment Outcome	2007
Hepatic steatosis in hepatitis C: comparison of diabetic and nondiabetic patients in the hepatitis C antiviral long-term treatment against cirrhosis trial. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2007, Volume: 5, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Diabetes Mellitus; Disease Progression; Fatty Liver; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Prevalence; Prospective Studies; Recombinant Proteins; Ribavirin; Risk Factors	2007
Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. Gastroenterology, 2007, Volume: 132, Issue:5 Topics: Adolescent; Adult; Aged; Antiviral Agents; Biopsy; Darbepoetin alfa; Disease Progression; Dose-Response Relationship, Drug; Erythropoietin; Female; Hematinics; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Portal Pressure; Recombinant Proteins; Ribavirin; Secondary Prevention	2007
Mutation rate of the hepatitis C virus NS5B in patients undergoing treatment with ribavirin monotherapy. Gastroenterology, 2007, Volume: 132, Issue:5 Topics: Adult; Aged; Antiviral Agents; Cross-Over Studies; Disease Progression; DNA, Viral; Dose-Response Relationship, Drug; Double-Blind Method; Drug Resistance, Viral; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Mutagenesis; Ribavirin; Time Factors; Viral Nonstructural Proteins; Viral Proteins	2007
Hepatic iron accumulation is associated with disease progression and resistance to interferon/ribavirin combination therapy in chronic hepatitis C. Journal of gastroenterology and hepatology, 2007, Volume: 22, Issue:11 Topics: Adult; Aged; Alcohol Drinking; Antiviral Agents; Disease Progression; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Female; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Iron; Iron Overload; Liver; Male; Middle Aged; Platelet Count; Recombinant Proteins; Ribavirin; Risk Factors; Severity of Illness Index; Sex Factors; Transaminases; Treatment Outcome	2007

Other Studies

146 other study(ies) available for ribavirin and Disease Exacerbation

Article	Year
Hepatitis C therapy with direct antiviral agents in patients with advanced chronic kidney disease: real-world experience of the German Hepatitis C-Registry (Deutsches Hepatitis C-Register). European journal of gastroenterology & hepatology, 2019, Volume: 31, Issue:11 Topics: 2-Naphthylamine; Acute Disease; Adult; Aged; Anemia; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Disease Progression; Drug Therapy, Combination; Female; Fluorenes; Germany; Glomerular Filtration Rate; Hepatitis C, Chronic; Humans; Hypertension; Imidazoles; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Pleural Effusion; Proline; Pyrrolidines; Registries; Renal Insufficiency, Chronic; Ribavirin; Ritonavir; RNA, Viral; Severity of Illness Index; Simeprevir; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Uracil; Uridine Monophosphate; Valine	2019
Association between PNPLA3[G]/I148M variant, steatosis and fibrosis stage in hepatitis C virus - genetic matters. Journal of physiology and pharmacology : an official journal of the Polish Physiological Society, 2019, Volume: 70, Issue:4 Topics: Antiviral Agents; Disease Progression; Fatty Liver; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lipase; Liver; Liver Cirrhosis; Male; Membrane Proteins; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; RNA, Viral	2019
Long-term follow-up of patients with chronic hepatitis C treated with α-interferon and ribavirin antiviral therapy: clinical and fibrosis impact of treatment response. European journal of gastroenterology & hepatology, 2017, Volume: 29, Issue:7 Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Disease Progression; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Kaplan-Meier Estimate; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Proportional Hazards Models; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; Sustained Virologic Response; Time Factors; Treatment Outcome	2017
The Italian compassionate use of sofosbuvir observational cohort study for the treatment of recurrent hepatitis C: clinical and virological outcomes. Transplant international : official journal of the European Society for Organ Transplantation, 2017, Volume: 30, Issue:12 Topics: Analysis of Variance; Antiviral Agents; Cohort Studies; Compassionate Use Trials; Confidence Intervals; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Italy; Liver Cirrhosis; Liver Function Tests; Logistic Models; Male; Multivariate Analysis; Prognosis; Recurrence; Ribavirin; Risk Assessment; Severity of Illness Index; Sofosbuvir; Treatment Outcome	2017
Sofosbuvir and daclatasvir therapy in patients with hepatitis C-related advanced decompensated liver disease (MELD ≥ 15). Alimentary pharmacology & therapeutics, 2018, Volume: 47, Issue:3 Topics: Antiviral Agents; Australia; Carbamates; Compassionate Use Trials; Disease Progression; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Ribavirin; Sofosbuvir; Survival Analysis; Treatment Outcome; Valine	2018
Cost-effectiveness of daclatasvir plus asunaprevir for chronic hepatitis C genotype 1b treatment-naïve patients in China. PloS one, 2018, Volume: 13, Issue:4 Topics: Adult; Antiviral Agents; Carbamates; China; Cohort Studies; Cost-Benefit Analysis; Disease Progression; Female; Genotype; Health Care Costs; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Isoquinolines; Male; Markov Chains; Middle Aged; Monte Carlo Method; Polyethylene Glycols; Probability; Pyrrolidines; Quality of Life; Recombinant Proteins; Ribavirin; Sensitivity and Specificity; Sulfonamides; Treatment Outcome; Valine	2018
Differential Effect of HCV Eradication and Fibrosis Grade on Hepatocellular Carcinoma and All-cause Mortality. Scientific reports, 2018, 09-12, Volume: 8, Issue:1 Topics: Aged; Antiviral Agents; Carcinoma, Hepatocellular; Disease Progression; Female; Fibrosis; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Sustained Virologic Response	2018
Long-term histological change in chronic hepatitis C patients who had received peginterferon plus ribavirin therapy with sustained virological response. Journal of the Formosan Medical Association = Taiwan yi zhi, 2019, Volume: 118, Issue:7 Topics: Adult; Antiviral Agents; Disease Progression; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Sustained Virologic Response; Taiwan; Viral Load	2019
Successful treatment with ribavirine for chronic hepatitis E in chronic lymphocytic leukemia treated with Ibrutinib. Bulletin du cancer, 2019, Volume: 106, Issue:1 Topics: Adenine; Aged; Alemtuzumab; Antineoplastic Agents, Immunological; Antiviral Agents; Chronic Disease; Disease Progression; Hepatitis E; Hepatitis E virus; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Piperidines; Pyrazoles; Pyrimidines; Ribavirin	2019
European mitochondrial haplogroups predict liver-related outcomes in patients coinfected with HIV and HCV: a retrospective study. Journal of translational medicine, 2019, 07-26, Volume: 17, Issue:1 Topics: Adult; Antiviral Agents; Biopsy; Carcinoma, Hepatocellular; Coinfection; Disease Progression; DNA, Mitochondrial; Europe; Female; Genotype; Haplotypes; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Liver; Liver Failure; Liver Neoplasms; Male; Middle Aged; Proportional Hazards Models; Retrospective Studies; Ribavirin; Risk	2019
The natural history and long-term outcomes in patients with chronic hepatitis C genotype 4 after interferon-based therapy. Liver international : official journal of the International Association for the Study of the Liver, 2013, Volume: 33, Issue:6 Topics: Adult; Antiviral Agents; Biomarkers; Chi-Square Distribution; Disease Progression; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Multivariate Analysis; Phenotype; Retrospective Studies; Ribavirin; Risk Factors; RNA, Viral; Time Factors; Treatment Outcome; Viral Load	2013
Durability of the response to peginterferon-α2b and ribavirin in patients with chronic hepatitis C: a cohort study in the routine clinical setting. European journal of gastroenterology & hepatology, 2014, Volume: 26, Issue:1 Topics: Adult; Antiviral Agents; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; Glucose Metabolism Disorders; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Kaplan-Meier Estimate; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Polyethylene Glycols; Proportional Hazards Models; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; Risk Factors; RNA, Viral; Time Factors; Treatment Outcome; Viral Load	2014
Genetic variation near interleukin 28B and the risk of hepatocellular carcinoma in patients with chronic hepatitis C. Journal of gastroenterology, 2014, Volume: 49, Issue:7 Topics: Adult; Aged; Alanine Transaminase; alpha-Fetoproteins; Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Disease Progression; Drug Therapy, Combination; Female; Genetic Predisposition to Disease; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferon-beta; Interferons; Interleukins; Liver Neoplasms; Male; Middle Aged; Polymorphism, Single Nucleotide; Ribavirin	2014
Role of FDFT1 polymorphism for fibrosis progression in patients with chronic hepatitis C. Liver international : official journal of the International Association for the Study of the Liver, 2014, Volume: 34, Issue:3 Topics: Adult; Alleles; Antiviral Agents; Disease Progression; Farnesyl-Diphosphate Farnesyltransferase; Fatty Liver; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Risk Factors; RNA, Viral	2014
Recurrent hepatitis C virus infection and outcome after living-donor liver transplant. Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation, 2013, Volume: 11, Issue:6 Topics: Adult; Antiviral Agents; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; Graft Rejection; Hepacivirus; Hepatitis C; Humans; Incidence; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Living Donors; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; Time Factors; Treatment Outcome	2013
Baseline MELD score predicts hepatic decompensation during antiviral therapy in patients with chronic hepatitis C and advanced cirrhosis. PloS one, 2013, Volume: 8, Issue:8 Topics: Adult; Aged; Antiviral Agents; Ascites; Disease Progression; Female; Follow-Up Studies; Hemorrhage; Hepatitis C, Chronic; Hospitalization; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk; Withholding Treatment	2013
Histopathology of type C liver disease for determining hepatocellular carcinoma risk factors. World journal of gastroenterology, 2013, Aug-14, Volume: 19, Issue:30 Topics: Adult; Antiviral Agents; Biopsy; Carcinoma, Hepatocellular; Chi-Square Distribution; Disease Progression; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Incidence; Interferon-alpha; Japan; Kaplan-Meier Estimate; Liver; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Predictive Value of Tests; Proportional Hazards Models; Prospective Studies; Ribavirin; Risk Assessment; Risk Factors; Time Factors	2013
Cost-effectiveness analysis of triple therapy with protease inhibitors in treatment-naive hepatitis C patients. PharmacoEconomics, 2013, Volume: 31, Issue:10 Topics: Age Factors; Antiviral Agents; Clinical Trials as Topic; Cost-Benefit Analysis; Disease Progression; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Markov Chains; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin; Spain	2013
Lambda interferon serum levels in patients with chronic hepatitis C virus infection according to their response to therapy with pegylated interferon and ribavirin. Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research, 2014, Volume: 34, Issue:2 Topics: Adult; Biomarkers, Pharmacological; Disease Progression; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Immunity; Immunotherapy; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Retrospective Studies; Ribavirin; Viral Load	2014
Defer or treat? Reasons for treatment decisions in patients with chronic hepatitis C genotype 1 in the early era of directly acting antiviral agents. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2014, Volume: 46, Issue:1 Topics: Adult; Aged; Antiviral Agents; Cohort Studies; Decision Making; Disease Progression; Drug Carriers; Drug Discovery; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Logistic Models; Male; Middle Aged; Multivariate Analysis; Oligopeptides; Patient Preference; Polyethylene Glycols; Proline; Prospective Studies; Ribavirin; Severity of Illness Index; Time Factors; Watchful Waiting	2014
Liver fibrosis progression in HIV-HCV-coinfected patients treated with distinct antiretroviral drugs and impact of pegylated interferon/ribavirin therapy. Antiviral therapy, 2014, Volume: 19, Issue:3 Topics: Adult; Antiviral Agents; Disease Progression; Drug Interactions; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; RNA, Viral; Viral Load	2014
Progression of liver fibrosis in HIV/hepatitis C virus-coinfected individuals on antiretroviral therapy with early stages of liver fibrosis at baseline. HIV medicine, 2014, Volume: 15, Issue:4 Topics: Adult; Age Factors; Antiretroviral Therapy, Highly Active; Antiviral Agents; Coinfection; Disease Progression; Female; Hepatitis C; HIV Infections; Humans; Interferons; Liver Cirrhosis; Male; Prospective Studies; Retrospective Studies; Ribavirin; Risk Factors	2014
Host and viral determinants of the outcome of exposure to HCV infection genotype 4: a large longitudinal study. The American journal of gastroenterology, 2014, Volume: 109, Issue:2 Topics: Acute Disease; Adult; Age Distribution; Antiviral Agents; Case-Control Studies; Confidence Intervals; Disease Progression; Egypt; Female; GB virus C; Genotype; Hepacivirus; Hepatitis C; Humans; Incidence; Interferons; Interleukins; Kaplan-Meier Estimate; Longitudinal Studies; Male; Middle Aged; Polymorphism, Single Nucleotide; Prognosis; Prospective Studies; Ribavirin; RNA, Viral; Sex Distribution; Statistics, Nonparametric; Treatment Outcome; Viral Load; Viremia	2014
Hepatitis E-associated encephalopathy in a renal transplant recipient. BMJ case reports, 2014, Apr-30, Volume: 2014 Topics: Aged; Biopsy, Needle; Chronic Disease; Disease Progression; Electromyography; Female; Follow-Up Studies; Graft Survival; Hepatic Encephalopathy; Hepatitis E; Humans; Immunocompromised Host; Immunohistochemistry; Kidney Failure, Chronic; Kidney Transplantation; Liver Function Tests; Magnetic Resonance Imaging; Ribavirin; Severity of Illness Index; Transplant Recipients; Transplantation Immunology; Treatment Outcome; Viral Load	2014
Influence of psychiatric diagnosis on treatment uptake and interferon side effects in patients with hepatitis C. Journal of gastroenterology and hepatology, 2014, Volume: 29, Issue:6 Topics: Adult; Antiviral Agents; Depression; Disease Progression; Female; Hepatitis C; Humans; Interferon-alpha; Male; Mental Disorders; Middle Aged; Multivariate Analysis; Ribavirin; Schizophrenia	2014
Effects of sustained viral response in patients with HIV and chronic hepatitis C and nonadvanced liver fibrosis. Journal of acquired immune deficiency syndromes (1999), 2014, Jul-01, Volume: 66, Issue:3 Topics: Adult; Alanine Transaminase; Antiviral Agents; CD4 Lymphocyte Count; Cohort Studies; Disease Progression; Drug Therapy, Combination; Elasticity Imaging Techniques; Female; Follow-Up Studies; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Liver Cirrhosis; Logistic Models; Male; Predictive Value of Tests; Ribavirin; RNA, Viral; Viral Load	2014
Lower incidence of hepatocellular carcinoma and cirrhosis in hepatitis C patients with sustained virological response by pegylated interferon and ribavirin. Digestive diseases and sciences, 2015, Volume: 60, Issue:2 Topics: Adult; Antiviral Agents; Biomarkers; Carcinoma, Hepatocellular; Chi-Square Distribution; Disease Progression; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Kaplan-Meier Estimate; Liver Cirrhosis; Liver Neoplasms; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Polyethylene Glycols; Protective Factors; Recombinant Proteins; Republic of Korea; Retrospective Studies; Ribavirin; Risk Factors; RNA, Viral; Time Factors; Treatment Outcome; Viral Load	2015
Drug eruptions induced by telaprevir in patients with chronic hepatitis C virus genotype 1 infection: a prospective study. Actas dermo-sifiliograficas, 2015, Volume: 106, Issue:3 Topics: Adult; Aged; Disease Progression; Drug Eruptions; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Oligopeptides; Prospective Studies; Ribavirin; Serine Proteinase Inhibitors; Severity of Illness Index	2015
Cost-effectiveness model for hepatitis C screening and treatment: Implications for Egypt and other countries with high prevalence. Global public health, 2015, Volume: 10, Issue:3 Topics: Antiviral Agents; Cost-Benefit Analysis; Decision Trees; Disease Progression; Drug Therapy, Combination; Egypt; Enzyme-Linked Immunosorbent Assay; Hepatitis C; Humans; Incidence; Interferons; Markov Chains; Mass Screening; Models, Economic; Polymerase Chain Reaction; Prevalence; Quality of Life; Ribavirin; Sofosbuvir; Uridine Monophosphate	2015
Cost-effectiveness analysis of simeprevir in combination with peginterferon and ribavirin for treatment-naïve chronic hepatitis C genotype 1 patients in Japan. Journal of medical economics, 2015, Volume: 18, Issue:7 Topics: Antiviral Agents; Cost-Benefit Analysis; Disease Progression; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferons; Japan; Male; Markov Chains; Meta-Analysis as Topic; Middle Aged; Models, Econometric; Phenotype; Randomized Controlled Trials as Topic; Ribavirin; Simeprevir	2015
Cost-effectiveness of novel regimens for the treatment of hepatitis C virus. Annals of internal medicine, 2015, Mar-17, Volume: 162, Issue:6 Topics: Antiviral Agents; Benzimidazoles; Carbamates; Cost-Benefit Analysis; Disease Progression; Drug Costs; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Interferon-alpha; Patient-Specific Modeling; Pyrrolidines; Ribavirin; Sensitivity and Specificity; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate; Valine	2015
Fibrosing cholestatic hepatitis after successful interferon and ribavirin therapy for recurrent hepatitis C post living related liver transplantation: a case report. Osaka city medical journal, 2014, Volume: 60, Issue:2 Topics: Adult; Allografts; Antiviral Agents; Biopsy; Cholestasis, Intrahepatic; Disease Progression; Drug Therapy, Combination; Fatal Outcome; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Interferons; Liver Cirrhosis; Liver Transplantation; Living Donors; Male; Recurrence; Ribavirin; Severity of Illness Index; Time Factors; Treatment Outcome	2014
The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection. Annals of internal medicine, 2015, May-05, Volume: 162, Issue:9 Topics: Antiviral Agents; Cost-Benefit Analysis; Disease Progression; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Markov Chains; Monte Carlo Method; Quality-Adjusted Life Years; Ribavirin; Sofosbuvir; United States; Uridine Monophosphate	2015
Boceprevir for Chronic Genotype 1 Hepatitis C Virus in the Current Health Care Setting in Greece: A Cost-effectiveness Analysis. Clinical therapeutics, 2015, Jul-01, Volume: 37, Issue:7 Topics: Antiviral Agents; Cost-Benefit Analysis; Disease Progression; Drug Costs; Drug Therapy, Combination; Genotype; Greece; Health Care Costs; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Life Expectancy; Markov Chains; Models, Econometric; Polyethylene Glycols; Proline; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin; Sensitivity and Specificity	2015
Utility of the low-accelerating-dose regimen in 182 liver recipients with recurrent hepatitis C virus. World journal of gastroenterology, 2015, May-28, Volume: 21, Issue:20 Topics: Antiviral Agents; Biopsy; Disease Progression; Drug Therapy, Combination; End Stage Liver Disease; Female; Genotype; Graft Survival; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Interferons; Interleukins; Liver Transplantation; Male; Middle Aged; New York City; Polyethylene Glycols; Proportional Hazards Models; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; Risk Factors; Time Factors; Treatment Outcome; Viral Load; Virus Activation	2015
Impact of fibrosis progression on clinical outcome in patients treated for post-transplant hepatitis C recurrence. Liver international : official journal of the International Association for the Study of the Liver, 2015, Volume: 35, Issue:11 Topics: Adult; Antiviral Agents; Biopsy; Disease Progression; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Kaplan-Meier Estimate; Liver; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Proportional Hazards Models; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; Survival Rate; Treatment Outcome; Viral Load	2015
Cost-effectiveness of Interferon-free therapy for Hepatitis C in Germany--an application of the efficiency frontier approach. BMC infectious diseases, 2015, Jul-30, Volume: 15 Topics: Antiviral Agents; Cost-Benefit Analysis; Disease Progression; Drug Costs; Drug Therapy, Combination; Female; Genotype; Germany; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Proline; Ribavirin; Simeprevir; Sofosbuvir; Treatment Outcome	2015
Low-density lipoprotein receptor genetic polymorphism in chronic hepatitis C virus Egyptian patients affects treatment response. World journal of gastroenterology, 2015, Oct-21, Volume: 21, Issue:39 Topics: Adult; Antiviral Agents; Case-Control Studies; Disease Progression; Drug Therapy, Combination; Egypt; Exons; Female; Gene Frequency; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Pharmacogenetics; Phenotype; Polyethylene Glycols; Polymorphism, Genetic; Receptors, LDL; Recombinant Proteins; Remission Induction; Ribavirin; Treatment Outcome	2015
Association of sustained virologic response with reduced progression to liver cirrhosis in elderly patients with chronic hepatitis C. Clinical interventions in aging, 2016, Volume: 11 Topics: Aged; Antiviral Agents; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Liver Cirrhosis; Male; Proportional Hazards Models; Retrospective Studies; Ribavirin; Taiwan; Treatment Outcome; Ultrasonography	2016
α-fetoprotein levels after interferon therapy predict regression of liver fibrosis in patients with sustained virological response. Journal of gastroenterology and hepatology, 2016, Volume: 31, Issue:5 Topics: Aged; alpha-Fetoproteins; Antiviral Agents; Area Under Curve; Biomarkers; Biopsy; Chi-Square Distribution; Disease Progression; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Predictive Value of Tests; Remission Induction; Retrospective Studies; Ribavirin; ROC Curve; Severity of Illness Index; Sustained Virologic Response; Time Factors; Treatment Outcome	2016
Early Treatment in HCV: Is it a Cost-Utility Option from the Italian Perspective? Clinical drug investigation, 2016, Volume: 36, Issue:8 Topics: Antiviral Agents; Cost-Benefit Analysis; Disease Progression; Hepatitis C, Chronic; Humans; Interferons; Italy; Liver Cirrhosis; Markov Chains; Monte Carlo Method; Quality-Adjusted Life Years; Ribavirin; Simeprevir; Treatment Outcome	2016
Cost-Effectiveness of Genotype 1 Chronic Hepatitis C Virus Treatments in Patients Coinfected with Human Immunodeficiency Virus in the United States. Advances in therapy, 2016, Volume: 33, Issue:8 Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Cyclopropanes; Disease Progression; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Lactams, Macrocyclic; Liver Cirrhosis; Liver Neoplasms; Macrocyclic Compounds; Markov Chains; Middle Aged; Polyethylene Glycols; Proline; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin; Ritonavir; Sofosbuvir; Sulfonamides; United States; Uracil; Valine	2016
Liver fibrosis progression and clinical outcomes are intertwined: role of CD4+ T-cell count and NRTI exposure from a large cohort of HIV/HCV-coinfected patients with detectable HCV-RNA: A MASTER cohort study. Medicine, 2016, Volume: 95, Issue:29 Topics: Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Coinfection; Disease Progression; Female; Hepatitis C; HIV Infections; Humans; Incidence; Interferons; Kaplan-Meier Estimate; Liver Cirrhosis; Longitudinal Studies; Male; Retrospective Studies; Ribavirin; Risk Factors; RNA, Viral; Treatment Outcome	2016
Estimation of direct medical cost related to the management of chronic hepatitis C and its complications in South Korea. Medicine, 2016, Volume: 95, Issue:30 Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carcinoma, Hepatocellular; Disease Progression; Female; Health Care Costs; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Republic of Korea; Retrospective Studies; Ribavirin; Sustained Virologic Response; Young Adult	2016
Aspartate aminotransferase to platelet ratio index and sustained virologic response are associated with progression from hepatitis C associated liver cirrhosis to hepatocellular carcinoma after treatment with pegylated interferon plus ribavirin. Clinical interventions in aging, 2016, Volume: 11 Topics: Aged; Antiviral Agents; Aspartate Aminotransferases; Blood Platelets; Carcinoma, Hepatocellular; Disease Progression; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Kaplan-Meier Estimate; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Retrospective Studies; Ribavirin; Risk Factors; Sustained Virologic Response; Taiwan	2016
The clinical outcomes of chronic hepatitis C in South Korea: A prospective, multicenter cohort study. Medicine, 2016, Volume: 95, Issue:35 Topics: Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Disease Progression; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Incidence; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Republic of Korea; Ribavirin; Risk Factors; Survival Rate; Sustained Virologic Response	2016
Optimal timing for hepatitis C therapy in US patients eligible for liver transplantation: a cost-effectiveness analysis. Alimentary pharmacology & therapeutics, 2016, Volume: 44, Issue:10 Topics: Antiviral Agents; Benzimidazoles; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Disease Progression; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Neoplasm Recurrence, Local; Quality-Adjusted Life Years; Ribavirin; Sofosbuvir; United States	2016
HCV Resistance Profile Evolution in a GT1b, DAA-Naive Patient Before, On, and After Failing Triple DAA Therapy. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2017, Volume: 15, Issue:2 Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Disease Progression; Drug Combinations; Drug Resistance, Viral; Hepacivirus; Hepatitis C, Chronic; High-Throughput Nucleotide Sequencing; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; RNA, Viral; Sulfonamides; Sustained Virologic Response; Treatment Failure; Uracil; Valine; Viral Nonstructural Proteins	2017
Interleukin 10 gene single nucleotide polymorphisms in Polish patients with chronic hepatitis C: Analysis of association with severity of disease and treatment outcome. Human immunology, 2017, Volume: 78, Issue:2 Topics: Adult; Disease Progression; Drug Therapy, Combination; Female; Fibrosis; Gene Frequency; Genotype; Hepatitis C, Chronic; Humans; Inflammation; Interferon-alpha; Interleukin-10; Liver; Male; Middle Aged; Poland; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Treatment Outcome; Young Adult	2017
Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: Analysis of data from the Hepa-C registry. Hepatology (Baltimore, Md.), 2017, Volume: 65, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Cause of Death; Cohort Studies; Disease Progression; End Stage Liver Disease; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Kaplan-Meier Estimate; Liver Cirrhosis; Liver Function Tests; Logistic Models; Male; Middle Aged; Multivariate Analysis; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Registries; Retrospective Studies; Ribavirin; Risk Assessment; Severity of Illness Index; Sofosbuvir; Spain; Survival Analysis; Treatment Outcome	2017
[The analysis of the hepatitis C virus infection course and efficacy of treatment dependence on HLA A antigens in children and youth]. Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 2008, Volume: 25, Issue:146 Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Disease Progression; Female; Hepatitis C; HLA-A Antigens; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Male; Polyethylene Glycols; Prognosis; Recombinant Proteins; Ribavirin	2008
Treatment of late stage disease in a model of arenaviral hemorrhagic fever: T-705 efficacy and reduced toxicity suggests an alternative to ribavirin. PloS one, 2008, Volume: 3, Issue:11 Topics: Absorption; Administration, Oral; Alanine Transaminase; Amides; Animals; Arenaviridae Infections; Aspartate Aminotransferases; Cricetinae; Disease Models, Animal; Disease Progression; Female; Hemorrhagic Fevers, Viral; Interferon Type I; Liver Diseases; Mesocricetus; Pichinde virus; Pyrazines; Ribavirin; Survival Analysis; Treatment Outcome; Viral Load	2008
Hepatitis C virus therapy in liver transplant recipients: response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2008, Volume: 14, Issue:12 Topics: Adult; Aged; Antiviral Agents; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Prognosis; Ribavirin; Secondary Prevention; Treatment Outcome; Young Adult	2008
Serum ferritin as a predictor of treatment outcome in patients with chronic hepatitis C. The American journal of gastroenterology, 2009, Volume: 104, Issue:3 Topics: Adult; Antiviral Agents; Disease Progression; Female; Ferritins; Hemolysis; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Iron; Liver; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Transferrin; Treatment Outcome	2009
Histological response study of chronic viral hepatitis C patients treated with interferon alone or combined with ribavirin. The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases, 2008, Volume: 12, Issue:5 Topics: Adult; Antiviral Agents; Combined Modality Therapy; Disease Progression; Female; Hepatitis C, Chronic; Humans; Interferons; Liver; Liver Cirrhosis; Male; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome	2008
High sustained virological response rate to combination therapy in genotype 1 patients with histologically mild hepatitis C. Journal of gastrointestinal and liver diseases : JGLD, 2009, Volume: 18, Issue:1 Topics: Adult; Age Factors; Antiviral Agents; Biomarkers; Disease Progression; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Assessment; Risk Factors; RNA, Viral; Romania; Severity of Illness Index; Time Factors; Transaminases; Treatment Outcome; Viral Load	2009
Interleukin 18 promoter variants (-137G>C and -607C>A) in patients with chronic hepatitis C: association with treatment response. Journal of clinical immunology, 2009, Volume: 29, Issue:5 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Disease Progression; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interleukin-18; Male; Middle Aged; Polymorphism, Genetic; Prognosis; Promoter Regions, Genetic; Ribavirin; RNA, Viral; Treatment Outcome	2009
Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus/hepatitis C virus. Hepatology (Baltimore, Md.), 2009, Volume: 50, Issue:4 Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Biopsy; Cohort Studies; Disease Progression; Female; Hepacivirus; Hepatitis C; HIV; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors	2009
Impact of pegylated interferon and ribavirin on morbidity and mortality in patients with chronic hepatitis C and normal aminotransferases in France. Hepatology (Baltimore, Md.), 2009, Volume: 50, Issue:5 Topics: Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; Child; Child, Preschool; Disease Progression; Drug Therapy, Combination; Female; France; Hepatitis C, Chronic; Humans; Infant; Infant, Newborn; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Patient Selection; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Sensitivity and Specificity; Young Adult	2009
High levels of chronic immune activation in the T-cell compartments of patients coinfected with hepatitis C virus and human immunodeficiency virus type 1 and on highly active antiretroviral therapy are reverted by alpha interferon and ribavirin treatment. Journal of virology, 2009, Volume: 83, Issue:21 Topics: ADP-ribosyl Cyclase 1; Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; Disease Progression; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon-alpha; Lymphocyte Activation; Male; Middle Aged; Ribavirin; T-Lymphocyte Subsets; T-Lymphocytes; Viral Load; Young Adult	2009
Maintenance ribavirin monotherapy delays fibrosis progression in liver transplant recipients with recurrent hepatitis C at high risk of progression. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2010, Volume: 42, Issue:4 Topics: Antiviral Agents; Disease Progression; Female; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Postoperative Complications; Prospective Studies; Recurrence; Ribavirin	2010
[Treatment of cirrhotics]. Acta gastroenterologica Latinoamericana, 2005, Volume: 35 Suppl 1 Topics: Antiviral Agents; Disease Progression; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral	2005
[Treatment of patients with normal liver aminotransferases]. Acta gastroenterologica Latinoamericana, 2005, Volume: 35 Suppl 1 Topics: Antiviral Agents; Disease Progression; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Reference Values; Ribavirin; Transaminases	2005
Treating hepatitis C in patients with cirrhosis: the effort is worth it. Journal of hepatology, 2010, Volume: 52, Issue:5 Topics: Antiviral Agents; Disease Progression; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Polyethylene Glycols; Recombinant Proteins; Recurrence; Reproducibility of Results; Ribavirin; Treatment Outcome	2010
Peginterferon alpha-2b and acute allograft failure in a heart transplant recipient. The Annals of thoracic surgery, 2010, Volume: 89, Issue:5 Topics: Acute Disease; Antiviral Agents; Autopsy; Disease Progression; Fatal Outcome; Graft Rejection; Heart Transplantation; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Assessment; Time Factors; Transplantation, Homologous	2010
An economic analysis of antiviral therapy in patients with advanced hepatitis C virus disease: still not there! Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2010, Volume: 16, Issue:6 Topics: Antiviral Agents; Cost Savings; Decision Support Techniques; Disease Progression; Drug Administration Schedule; Drug Costs; Drug Therapy, Combination; Graft Rejection; Graft Survival; Hepacivirus; Hepatitis C; Humans; Interferons; Liver Cirrhosis; Liver Transplantation; Markov Chains; Patient Selection; Quality-Adjusted Life Years; Recurrence; Ribavirin; Severity of Illness Index; Time Factors; Treatment Outcome; Viral Load	2010
Timing of hepatitis C antiviral therapy in patients with advanced liver disease: a decision analysis model. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2010, Volume: 16, Issue:6 Topics: Antiviral Agents; Carcinoma, Hepatocellular; Cost Savings; Decision Support Techniques; Disease Progression; Drug Administration Schedule; Drug Costs; Drug Therapy, Combination; Genotype; Graft Rejection; Graft Survival; Hepacivirus; Hepatitis C; Humans; Interferons; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Markov Chains; Middle Aged; Patient Selection; Quality-Adjusted Life Years; Recurrence; Ribavirin; RNA, Viral; Severity of Illness Index; Time Factors; Treatment Outcome; Viral Load	2010
Interferon alpha-induced hashimoto thyroiditis followed by transient graves disease in a patient with chronic HCV infection. Southern medical journal, 2010, Volume: 103, Issue:6 Topics: Adult; Antiviral Agents; Autoantibodies; Autoantigens; Disease Progression; Drug Therapy, Combination; Follow-Up Studies; Graves Disease; Hashimoto Disease; Hepatitis C, Chronic; Humans; Hypothyroidism; Interferon alpha-2; Interferon-alpha; Iodide Peroxidase; Iron-Binding Proteins; Male; Polyethylene Glycols; Receptors, Thyrotropin; Recombinant Proteins; Ribavirin; Th1 Cells; Th2 Cells	2010
In vivo ribavirin activity against severe pandemic H1N1 Influenza A/Mexico/4108/2009. The Journal of general virology, 2010, Volume: 91, Issue:Pt 12 Topics: Animals; Antiviral Agents; Chick Embryo; Disease Models, Animal; Disease Progression; Female; Influenza A Virus, H1N1 Subtype; Lung; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Microbial Sensitivity Tests; Orthomyxoviridae Infections; Ribavirin; Survival Analysis	2010
Effect of oral ribavirin treatment on the viral load and disease progression in Crimean-Congo hemorrhagic fever. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2011, Volume: 15, Issue:1 Topics: Administration, Oral; Adult; Aged; Antiviral Agents; Case-Control Studies; Disease Progression; Female; Hemorrhagic Fever Virus, Crimean-Congo; Hemorrhagic Fever, Crimean; Humans; Male; Middle Aged; Ribavirin; Treatment Outcome; Viral Load; Young Adult	2011
Effect of maintenance therapy with low-dose peginterferon for recurrent hepatitis C after living donor liver transplantation. Journal of viral hepatitis, 2012, Volume: 19, Issue:1 Topics: Adolescent; Adult; Aged; Antiviral Agents; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Liver Transplantation; Living Donors; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome; Young Adult	2012
A comparison of the natural history and outcome of treatment for Asian and non-Asian hepatitis C-infected patients. Journal of viral hepatitis, 2011, Volume: 18, Issue:7 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Asia; Child; Child, Preschool; Disease Progression; Female; Hepatitis C; Humans; Infant; Interferon-beta; Interferons; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Ribavirin; Risk Factors; Treatment Outcome	2011
Human cytomegalovirus infection inhibits response of chronic hepatitis-C-virus-infected patients to interferon-based therapy. Journal of gastroenterology and hepatology, 2011, Volume: 26, Issue:1 Topics: Adult; Antibodies, Viral; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Disease Progression; DNA, Viral; Drug Therapy, Combination; Egypt; Female; Genotype; Hepacivirus; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Polyethylene Glycols; Recombinant Proteins; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Envelope Proteins; Viral Load; Virus Activation	2011
The natural history of acute hepatitis C: clinical presentation, laboratory findings and treatment outcomes. Alimentary pharmacology & therapeutics, 2011, Volume: 33, Issue:5 Topics: Acute Disease; Adult; Aged; Antiviral Agents; Disease Progression; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin; Severity of Illness Index; Time Factors; Treatment Outcome; Young Adult	2011
Amino acid substitution in the core protein has no impact on relapse in hepatitis C genotype 1 patients treated with peginterferon and ribavirin. Journal of medical virology, 2011, Volume: 83, Issue:3 Topics: Adult; Aged; Amino Acid Substitution; Antiviral Agents; Disease Progression; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Mutation; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome; Viral Core Proteins; Viral Load	2011
Safety and efficacy of peginterferon alpha plus ribavirin in patients with chronic hepatitis C and coexisting heart disease. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2011, Volume: 43, Issue:5 Topics: Adult; Aged; Antiviral Agents; Disease Progression; Echocardiography; Electrocardiography; Female; Genotype; Heart Diseases; Hepacivirus; Hepatitis C, Chronic; Humans; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Troponin I	2011
Medical resource utilisation and healthcare costs in patients with chronic hepatitis C viral infection and thrombocytopenia. Journal of medical economics, 2011, Volume: 14, Issue:2 Topics: Antiviral Agents; Blood Transfusion; Disease Progression; Female; Health Care Costs; Health Resources; Hepatitis C, Chronic; Humans; Inpatients; Insurance Claim Review; Interferons; Male; Middle Aged; Outpatients; Platelet Count; Regression Analysis; Retrospective Studies; Ribavirin; Thrombocytopenia; United States	2011
Possible role of angiotensin-converting enzyme polymorphism on progression of hepatic fibrosis in chronic hepatitis C virus infection. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2011, Volume: 105, Issue:7 Topics: Adult; Antiviral Agents; Disease Progression; Female; Genetic Predisposition to Disease; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Peptidyl-Dipeptidase A; Polyethylene Glycols; Polymerase Chain Reaction; Polymorphism, Genetic; Recombinant Proteins; Ribavirin	2011
Pretreatment prediction of anemia progression by pegylated interferon alpha-2b plus ribavirin combination therapy in chronic hepatitis C infection: decision-tree analysis. Journal of gastroenterology, 2011, Volume: 46, Issue:9 Topics: Adult; Aged; Anemia, Hemolytic; Antiviral Agents; Cohort Studies; Decision Trees; Disease Progression; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Reproducibility of Results; Retrospective Studies; Ribavirin; Severity of Illness Index	2011
Impact of hepatitis C triple therapy availability upon the number of patients to be treated and associated costs in France: a model-based analysis. Gut, 2012, Volume: 61, Issue:2 Topics: Adolescent; Adult; Aged; Antiviral Agents; Computer Simulation; Disease Progression; Drug Costs; Drug Therapy, Combination; Drug Utilization; France; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Markov Chains; Middle Aged; Models, Economic; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Ribavirin; Young Adult	2012
Hepatitis C. Releve epidemiologique hebdomadaire, 2011, Oct-07, Volume: 86, Issue:41 Topics: Antiviral Agents; Disease Progression; Drug Therapy, Combination; Hepatitis C; Humans; Interferons; Ribavirin; Viral Hepatitis Vaccines; World Health Organization	2011
Predictors of changes in hemoglobin levels in patients with chronic hepatitis C treated with ribavirin plus pegylated interferon-α. Renal failure, 2012, Volume: 34, Issue:4 Topics: Administration, Oral; Anemia; Antiviral Agents; Biomarkers; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Incidence; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Risk Factors; RNA, Viral; Taiwan	2012
Early virological response in 1220 patients with HCV (genotype lb) chronic hepatitis and cirrhosis treated with PegInterferon plus Ribavirin. Romanian journal of internal medicine = Revue roumaine de medecine interne, 2011, Volume: 49, Issue:2 Topics: Adult; Antiviral Agents; Biopsy; Disease Progression; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Risk Assessment; Risk Factors; Romania; Time Factors; Treatment Failure; Treatment Outcome; Viral Load	2011
New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis. Annals of internal medicine, 2012, Feb-21, Volume: 156, Issue:4 Topics: Antiviral Agents; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Decision Support Techniques; Disease Progression; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Liver Cirrhosis; Liver Neoplasms; Male; Markov Chains; Medication Adherence; Protease Inhibitors; Quality-Adjusted Life Years; Ribavirin; Risk Factors; Treatment Outcome	2012
Oral versus inhaled ribavirin therapy for respiratory syncytial virus infection after lung transplantation. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, 2012, Volume: 31, Issue:8 Topics: Administration, Inhalation; Administration, Oral; Adolescent; Adult; Aged; Antiviral Agents; Disease Progression; Female; Humans; Lung Transplantation; Male; Middle Aged; Respiratory Syncytial Virus Infections; Retrospective Studies; Ribavirin; Severity of Illness Index; Survival Rate; Treatment Outcome; Young Adult	2012
The interaction between insulin resistance, liver fibrosis and early virological response in Egyptian patients with chronic hepatitis C. Canadian journal of gastroenterology = Journal canadien de gastroenterologie, 2012, Volume: 26, Issue:6 Topics: Adult; Age Factors; Antiviral Agents; Biopsy; Chi-Square Distribution; Disease Progression; Drug Therapy, Combination; Egypt; Enzyme-Linked Immunosorbent Assay; Female; Hepatitis C, Chronic; Humans; Insulin Resistance; Interferon-alpha; Liver Cirrhosis; Logistic Models; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Factors; Severity of Illness Index; Viral Load	2012
Long-term antiviral treatment for recurrent hepatitis C after liver transplantation. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2012, Volume: 44, Issue:10 Topics: Adult; Aged; Antiviral Agents; Disease Progression; Drug Therapy, Combination; Female; Hepatitis C; Humans; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Liver; Liver Transplantation; Male; Middle Aged; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; RNA, Viral; Survival Rate	2012
Predicted effects of treatment for HCV infection vary among European countries. Gastroenterology, 2012, Volume: 143, Issue:4 Topics: Aged; Antiviral Agents; Carcinoma, Hepatocellular; Disease Progression; Drug Therapy, Combination; Europe; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Incidence; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Male; Markov Chains; Mass Screening; Middle Aged; Polyethylene Glycols; Protease Inhibitors; Ribavirin	2012
YKL-40-gene polymorphism affects acute cellular rejection and fibrosis progression after transplantation for hepatitis C virus-induced liver disease. Journal of gastroenterology and hepatology, 2013, Volume: 28, Issue:1 Topics: Adipokines; Adult; Antiviral Agents; Chitinase-3-Like Protein 1; Cyclosporine; Disease Progression; Drug Therapy, Combination; End Stage Liver Disease; Female; Genotype; Graft Rejection; Hepacivirus; Hepatitis C; Humans; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Lectins; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Mycophenolic Acid; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Sex Factors; Statistics, Nonparametric; Tacrolimus; Time Factors; Young Adult	2013
Clinical significance and functional studies of myeloid-derived suppressor cells in chronic hepatitis C patients. Journal of clinical immunology, 2013, Volume: 33, Issue:4 Topics: Adult; Antiviral Agents; Arginase; Cell Count; Disease Progression; Female; Hepatitis C, Chronic; Humans; Immunosuppression Therapy; Interferon-alpha; Lymphocyte Activation; Male; Middle Aged; Myeloid Cells; Ribavirin; RNA, Viral; T-Lymphocytes; Young Adult	2013
Durability of a sustained virological response, late clinical sequelae, and long-term changes in aspartate aminotransferase to the platelet ratio index after successful treatment with peginterferon/ribavirin for chronic hepatitis C: a prospective study. European journal of gastroenterology & hepatology, 2013, Volume: 25, Issue:7 Topics: Adult; Antiviral Agents; Aspartate Aminotransferases; Biomarkers; Carcinoma, Hepatocellular; Chi-Square Distribution; Disease Progression; Drug Therapy, Combination; Female; Greece; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Platelet Count; Polyethylene Glycols; Predictive Value of Tests; Prospective Studies; Recombinant Proteins; Ribavirin; Risk Factors; RNA, Viral; Time Factors; Treatment Outcome; Viral Load	2013
Is treatment failure for hepatitis C virus infection in HIV-positive drug users associated with a shift in HCV genotypes? Journal of acquired immune deficiency syndromes (1999), 2003, Apr-01, Volume: 32, Issue:4 Topics: Antiviral Agents; Disease Progression; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; HIV Seropositivity; Humans; Interferons; Liver Failure; Liver Function Tests; Ribavirin; Risk-Taking; Substance Abuse, Intravenous; Treatment Failure	2003
Mannan-binding lectin and hepatitis C infection. Clinical and experimental immunology, 2003, Volume: 132, Issue:1 Topics: Adult; Aged; Antiviral Agents; Case-Control Studies; Disease Progression; Disease Susceptibility; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Mannose-Binding Lectin; Middle Aged; Ribavirin	2003
Treatment of recurrent hepatitis C in liver transplant recipients: is there any histologic benefit? Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2003, Volume: 9, Issue:4 Topics: Adult; Antiviral Agents; Disease Progression; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; Treatment Failure	2003
Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA, 2003, Jun-04, Volume: 289, Issue:21 Topics: Adult; Aged; Anti-Inflammatory Agents; Antiviral Agents; Biomarkers; Communicable Diseases, Emerging; Comorbidity; Cough; Demography; Disease Outbreaks; Disease Progression; Dyspnea; Female; Fever; Hospitalization; Humans; Hydrocortisone; Infection Control; Intensive Care Units; Lung; Male; Middle Aged; Ontario; Proportional Hazards Models; Radiography; Respiration, Artificial; Retrospective Studies; Ribavirin; Severe Acute Respiratory Syndrome; Severe acute respiratory syndrome-related coronavirus; Statistics, Nonparametric; Survival Analysis	2003
Combination therapy with intraventricular interferon-alpha and ribavirin for subacute sclerosing panencephalitis and monitoring measles virus RNA by quantitative PCR assay. Brain & development, 2003, Volume: 25, Issue:5 Topics: Antiviral Agents; Blood; Cerebrospinal Fluid; Child; Disease Progression; Drug Therapy, Combination; Humans; Injections, Intraventricular; Interferon-alpha; Male; Measles virus; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA; RNA, Viral; Subacute Sclerosing Panencephalitis	2003
Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA, 2003, Jul-09, Volume: 290, Issue:2 Topics: Adult; Antiviral Agents; Cost-Benefit Analysis; Disease Progression; Drug Costs; Female; Health Care Costs; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Life Expectancy; Liver Cirrhosis; Male; Markov Chains; Polyethylene Glycols; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin; United States	2003
Some hepatitis C patients -- especially women -- don't really benefit from early therapy. Report on medical guidelines & outcomes research, 2003, Jul-25, Volume: 14, Issue:14 Topics: Cost-Benefit Analysis; Disease Progression; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Practice Guidelines as Topic; Quality of Life; Recombinant Proteins; Ribavirin; Sex Factors; Treatment Outcome; United States; Women	2003
Hepatitis C: treatment challenges. Professional nurse (London, England), 2003, Volume: 19, Issue:3 Topics: Antiviral Agents; Chronic Disease; Disease Progression; Drug Monitoring; Drug Therapy, Combination; Hepatitis C; Humans; Interferon-alpha; Patient Education as Topic; Ribavirin; Treatment Outcome	2003
Report of two children with subacute sclerosing panencephalitis displaying an atypical clinical course. The Journal of emergency medicine, 2004, Volume: 26, Issue:3 Topics: Antiviral Agents; Aphasia; Child; Child, Preschool; Disease Progression; Emergency Medicine; Fatal Outcome; Female; Gait Ataxia; Humans; Inosine Pranobex; Interferons; Male; Ribavirin; Subacute Sclerosing Panencephalitis; Treatment Outcome	2004
Hepatitis C: speaking out about the silent epidemic. Nursing management, 2001, Volume: 32, Issue:6 Topics: Adaptation, Psychological; Antiviral Agents; Biopsy; Disease Progression; Drug Therapy, Combination; Hepatitis C; Humans; Incidence; Interferon-alpha; Nurse's Role; Patient Education as Topic; Prevalence; Ribavirin; Risk Factors; United States	2001
Effect of ribavirin on the plasma viral DNA load in patients with disseminating adenovirus infection. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2004, Jun-01, Volume: 38, Issue:11 Topics: Adenovirus Infections, Human; Adenoviruses, Human; Adolescent; Antiviral Agents; Child; Child, Preschool; Disease Progression; DNA, Viral; Humans; Lymphocytes; Prospective Studies; Ribavirin; Stem Cell Transplantation; Treatment Outcome; Viral Load	2004
Cost-effectiveness of combination peginterferon alpha-2a and ribavirin compared with interferon alpha-2b and ribavirin in patients with chronic hepatitis C. The American journal of gastroenterology, 2004, Volume: 99, Issue:8 Topics: Antiviral Agents; Cost-Benefit Analysis; Disease Progression; Drug Therapy, Combination; Genotype; Health Care Costs; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; United States; Viral Load	2004
[Due to normal transaminase values, no further treatment. Hepatitis C patient "suddenly" has liver cirrhosis]. MMW Fortschritte der Medizin, 2004, May-06, Volume: 146, Issue:19 Topics: Antiviral Agents; Clinical Trials as Topic; Disease Progression; Drug Therapy, Combination; False Negative Reactions; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Function Tests; Polyethylene Glycols; Recombinant Proteins; Reference Values; Ribavirin; Transaminases	2004
Carriage of the apolipoprotein E-epsilon4 allele and histologic outcome of recurrent hepatitis C after antiviral treatment. American journal of clinical pathology, 2004, Volume: 122, Issue:3 Topics: Alleles; Antiviral Agents; Apolipoproteins E; Disease Progression; Female; Hepacivirus; Hepatitis C, Chronic; History, 16th Century; Humans; Interferons; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Polymerase Chain Reaction; Polymorphism, Genetic; Recurrence; Ribavirin	2004
Management and treatment of hepatitis C virus infection in HIV-infected adults: recommendations from the Veterans Affairs Hepatitis C Resource Center Program and National Hepatitis C Program Office. The American journal of gastroenterology, 2005, Volume: 100, Issue:10 Topics: Antiviral Agents; Disease Progression; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Severity of Illness Index	2005
[Retreatment of patients with chronic hepatitis C]. Acta medica Croatica : casopis Hravatske akademije medicinskih znanosti, 2005, Volume: 59, Issue:5 Topics: Antiviral Agents; Disease Progression; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Retreatment; Ribavirin; Treatment Failure	2005
Treatment of hepatitis C in HIV-infected patients: regularly reassess the benefits and risks. Prescrire international, 2005, Volume: 14, Issue:80 Topics: Acidosis, Lactic; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Clinical Trials as Topic; Cost-Benefit Analysis; Disease Progression; Drug Interactions; Drug Therapy, Combination; Fibrosis; Genotype; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin	2005
Ribavirin levels and haemoglobin decline in early virological responders and non-responders to hepatitis C virus combination therapy. Pharmacology, 2006, Volume: 76, Issue:3 Topics: Alanine Transaminase; Antiviral Agents; Blood Preservation; Chromatography, High Pressure Liquid; Disease Progression; Drug Monitoring; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Half-Life; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Polymerase Chain Reaction; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome	2006
Flow cytometry assay of myeloid dendritic cells (mDCs) in peripheral blood during acute hepatitis C: possible pathogenetic mechanisms. World journal of gastroenterology, 2006, Feb-21, Volume: 12, Issue:7 Topics: Acute Disease; Adult; Antiviral Agents; Case-Control Studies; CD11 Antigens; Cell Count; Dendritic Cells; Disease Progression; Drug Combinations; Female; Flow Cytometry; Hepatitis A; Hepatitis C; Humans; Interferons; Lipopolysaccharide Receptors; Male; Middle Aged; Myeloid Cells; Ribavirin	2006
Autoimmune disorders during interferon therapy in a patient with chronic hepatitis C infection: how many of them can be observed in a single patient? Journal of clinical gastroenterology, 2006, Volume: 40, Issue:4 Topics: Anemia, Hemolytic, Autoimmune; Antiviral Agents; Disease Progression; Hashimoto Disease; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin	2006
Cost-effectiveness of peginterferon alfa-2a (40kDa) plus ribavirin in patients with HIV and hepatitis C virus co-infection. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2006, Volume: 36, Issue:4 Topics: Age Distribution; Antiviral Agents; Cost-Benefit Analysis; Disease Progression; Drug Therapy, Combination; Female; Health Care Costs; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Markov Chains; Models, Economic; Polyethylene Glycols; Quality of Life; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin; Treatment Outcome; United States	2006
The impact of nonalcoholic fatty liver disease and the metabolic syndrome on progression of fibrosis in patients with recurrent HCV after liver transplantation. Transplantation proceedings, 2006, Volume: 38, Issue:5 Topics: Adult; Antiviral Agents; Biopsy; Cholesterol, HDL; Disease Progression; Fatty Liver; Female; Hepatitis C; Humans; Liver Cirrhosis; Living Donors; Male; Metabolic Syndrome; Middle Aged; Postoperative Complications; Recurrence; Retrospective Studies; Ribavirin; Triglycerides	2006
Antiviral treatment withdrawal in viremic HCV-positive liver transplant patients: impact on viral loads, allograft function and morphology. Liver international : official journal of the International Association for the Study of the Liver, 2006, Volume: 26, Issue:7 Topics: Adult; Aged; Antiviral Agents; Disease Progression; Female; Hepacivirus; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Function Tests; Liver Transplantation; Male; Middle Aged; Recombinant Proteins; Ribavirin; Transplantation, Homologous; Viral Load; Viremia	2006
CCR5Delta32 mutation does not influence the susceptibility to HCV infection, severity of liver disease and response to therapy in patients with chronic hepatitis C. World journal of gastroenterology, 2006, Aug-07, Volume: 12, Issue:29 Topics: Adult; Alanine Transaminase; Alleles; Antiviral Agents; Case-Control Studies; Disease Progression; Drug Therapy, Combination; Female; Genetic Predisposition to Disease; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Mutation; Polyethylene Glycols; Receptors, CCR5; Recombinant Proteins; Ribavirin; Severity of Illness Index	2006
Anti-Golgi complex antibodies during pegylated-interferon therapy for hepatitis C. Liver international : official journal of the International Association for the Study of the Liver, 2006, Volume: 26, Issue:9 Topics: Alanine Transaminase; Antiviral Agents; Autoantibodies; Disease Progression; Drug Therapy, Combination; gamma-Glutamyltransferase; Golgi Apparatus; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral	2006
Early decline of hemoglobin correlates with progression of ribavirin-induced hemolytic anemia during interferon plus ribavirin combination therapy in patients with chronic hepatitis C. Journal of gastroenterology, 2006, Volume: 41, Issue:9 Topics: Adult; Aged; Anemia, Hemolytic; Antiviral Agents; Disease Progression; DNA, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome	2006
[Expert recommendations for the diagnosis and treatment of chronic hepatitis C infection in the prison setting]. Enfermedades infecciosas y microbiologia clinica, 2006, Volume: 24, Issue:9 Topics: Anti-HIV Agents; Antiviral Agents; Biopsy; Comorbidity; Disease Progression; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Function Tests; Patient Compliance; Polyethylene Glycols; Practice Guidelines as Topic; Prevalence; Prisoners; Prisons; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Spain; Substance Abuse, Intravenous; Treatment Outcome	2006
Immune response in addicts with chronic hepatitis C treated with interferon and ribavirin. Journal of gastroenterology and hepatology, 2007, Volume: 22, Issue:1 Topics: Adult; Antiviral Agents; Case-Control Studies; Chi-Square Distribution; Disease Progression; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Methadone; Opioid-Related Disorders; Recombinant Proteins; Ribavirin; Statistics, Nonparametric; Viral Load	2007
Impact of human immunodeficiency virus infection in patients infected with the hepatitis C virus. Liver international : official journal of the International Association for the Study of the Liver, 2007, Volume: 27, Issue:1 Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Disease Progression; Female; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Interferons; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Risk Factors; Viral Load	2007
[Assessment of the values of immune response mediators in patients with acute hepatitis C receiving combined antiviral therapy]. Klinicheskaia meditsina, 2006, Volume: 84, Issue:12 Topics: Acute Disease; Adolescent; Adult; Antiviral Agents; Biomarkers; Cytokines; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C; Humans; Immunoenzyme Techniques; Interferon-alpha; Male; Middle Aged; Polymerase Chain Reaction; Ribavirin; RNA, Viral; Treatment Outcome; Virus Replication	2006
Fibrosis progression in hepatitis C positive liver recipients after sustained virologic response to antiviral combination therapy (interferon-ribavirin therapy). Transplantation, 2007, Feb-15, Volume: 83, Issue:3 Topics: Adolescent; Adult; Aged; Antiviral Agents; Child; Disease Progression; Female; Fibrosis; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Secondary Prevention	2007
Peginterferon and ribavirin for hepatitis C. The New England journal of medicine, 2007, Mar-22, Volume: 356, Issue:12 Topics: Alcohol Drinking; Antiviral Agents; Disease Progression; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin	2007
Peginterferon and ribavirin for hepatitis C. The New England journal of medicine, 2007, Mar-22, Volume: 356, Issue:12 Topics: Antiviral Agents; Disease Progression; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Factors	2007
Association of polymorphisms in the first exon of mannose binding lectin gene (MBL2) in Brazilian patients with HCV infection. Clinical immunology (Orlando, Fla.), 2007, Volume: 124, Issue:1 Topics: Adult; Aged; Antiviral Agents; Brazil; Case-Control Studies; Disease Progression; Exons; Female; Gene Frequency; Genetic Predisposition to Disease; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Mannose-Binding Lectin; Middle Aged; Polyethylene Glycols; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Recombinant Proteins; Ribavirin; Treatment Outcome	2007
Recent advances in hepatitis C virus research and understanding the biology of the virus. World journal of gastroenterology, 2007, May-07, Volume: 13, Issue:17 Topics: Antiviral Agents; Biomedical Research; Disease Progression; Genome, Viral; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin	2007
Productivity improvements in hepatitis C treatment: impact on efficacy, cost, cost-effectiveness and quality of life. Scandinavian journal of gastroenterology, 2007, Volume: 42, Issue:7 Topics: Antiviral Agents; Cost-Benefit Analysis; Disease Progression; Drug Administration Schedule; Efficiency; Female; Genotype; Health Care Costs; Hepatitis C, Chronic; Humans; Interferons; Male; Markov Chains; Models, Economic; Quality of Life; Ribavirin; Treatment Outcome	2007
Chronic ductopenic rejection in patients with recurrent hepatitis C virus treated with pegylated interferon alfa-2a and ribavirin. Transplantation, 2007, Jul-27, Volume: 84, Issue:2 Topics: Adult; Antiviral Agents; Biopsy; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; Graft Rejection; Hepacivirus; Hepatitis C, Chronic; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Prognosis; Recombinant Proteins; Recurrence; Ribavirin; Risk Factors; RNA, Viral; Survival Rate	2007
Sudden hearing loss in chronic hepatitis C patient suffering from Turner syndrome, treated with pegylated interferon and ribavirin. International journal of audiology, 2007, Volume: 46, Issue:7 Topics: Adult; Antiviral Agents; Audiometry, Pure-Tone; Disease Progression; Drug Therapy, Combination; Female; Hearing Loss, Sensorineural; Hearing Loss, Sudden; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Severity of Illness Index; Turner Syndrome	2007
The cost-effectiveness of the new protocol reflecting rapid virologic response to peginterferon alpha-2b and ribavirin for chronic hepatitis C. European journal of gastroenterology & hepatology, 2007, Volume: 19, Issue:9 Topics: Antiviral Agents; Cost of Illness; Cost-Benefit Analysis; Disease Progression; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Japan; Markov Chains; Models, Econometric; Polyethylene Glycols; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin; RNA, Viral; Sensitivity and Specificity; Treatment Outcome; Viral Load	2007
Rate of cirrhosis progression reduced in HIV/HCV co-infected non-responders to anti-HCV therapy. The new microbiologica, 2007, Volume: 30, Issue:3 Topics: Antiviral Agents; Biomarkers; Child; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C; HIV; HIV Infections; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Italy; Liver Cirrhosis; Male; Poisson Distribution; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Failure; Treatment Outcome	2007
Iron and hepatitis C: beginning to make sense. Journal of gastroenterology and hepatology, 2007, Volume: 22, Issue:11 Topics: Alcohol Drinking; Antiviral Agents; Disease Progression; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Iron; Iron Overload; Liver; Phlebotomy; Platelet Count; Recombinant Proteins; Ribavirin; Risk Factors; Severity of Illness Index; Sex Factors; Transaminases; Treatment Failure; Treatment Outcome	2007
Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults. AIDS (London, England), 2007, Oct-18, Volume: 21, Issue:16 Topics: Adult; Alanine Transaminase; Anti-Retroviral Agents; Antiviral Agents; Aspartate Aminotransferases; Biomarkers; Biopsy; Disease Progression; Female; Fibrosis; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Incidence; Interferons; Liver; Logistic Models; Male; Middle Aged; Platelet Count; Predictive Value of Tests; Prospective Studies; Ribavirin	2007
Association between exposure to nevirapine and reduced liver fibrosis progression in patients with HIV and hepatitis C virus coinfection. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2008, Jan-01, Volume: 46, Issue:1 Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cross-Sectional Studies; Cyclopropanes; Disease Progression; Female; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Liver Cirrhosis; Male; Nevirapine; Protease Inhibitors; Retrospective Studies; Reverse Transcriptase Inhibitors; Ribavirin; Viral Load	2008
Progression of fibrosis in HIV and hepatitis C virus-coinfected patients treated with interferon plus ribavirin-based therapy: analysis of risk factors. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2008, Mar-01, Volume: 46, Issue:5 Topics: Adult; Anti-HIV Agents; Disease Progression; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Liver; Liver Cirrhosis; Male; Middle Aged; Mitochondria; Prevalence; Ribavirin; Risk Factors	2008
Efficacy of combined interferon and ribavirin for treatment of hepatitis C. Lancet (London, England), 1998, Jan-10, Volume: 351, Issue:9096 Topics: Adult; Antiviral Agents; Clinical Trials as Topic; Disease Progression; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Recombinant Proteins; Ribavirin; Time Factors	1998
Treatment of hepatitis C: a decision that needs careful consideration. The American journal of medicine, 1999, Volume: 107, Issue:2 Topics: Antiviral Agents; Disease Progression; DNA, Viral; Drug Administration Schedule; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferons; Ribavirin; Risk	1999
Long-term outcome of chronic hepatitis C virus infection in primary hypogammaglobulinaemia. QJM : monthly journal of the Association of Physicians, 1999, Volume: 92, Issue:8 Topics: Adolescent; Adult; Agammaglobulinemia; Antiviral Agents; Common Variable Immunodeficiency; Disease Progression; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Ribavirin	1999
Hepatitis C virus and human immunodeficiency virus: clinical issues in coinfection. The American journal of medicine, 1999, Dec-27, Volume: 107, Issue:6B Topics: Anti-HIV Agents; Antiviral Agents; Biopsy, Needle; Disease Progression; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Liver; Ribavirin	1999
[Treatment and prevention of hepatitis C]. La Revue du praticien, 2000, May-15, Volume: 50, Issue:10 Topics: Antiviral Agents; Clinical Protocols; Delayed-Action Preparations; Disease Progression; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Incidence; Interferon-alpha; Liver Cirrhosis; Prospective Studies; Ribavirin	2000
Treatment of progressive hepatitis C recurrence after liver transplantation with combination interferon plus ribavirin. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2001, Volume: 7, Issue:3 Topics: Adult; Aged; Antiviral Agents; Disease Progression; Female; Granulocyte Colony-Stimulating Factor; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Postoperative Complications; Recombinant Proteins; Recurrence; Ribavirin; Viral Load	2001
Managing chronic hepatitis C acquired through intravenous drug use. QJM : monthly journal of the Association of Physicians, 2001, Volume: 94, Issue:3 Topics: Adolescent; Adult; Antiviral Agents; Disease Progression; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon Type I; Liver Cirrhosis; Male; Middle Aged; Patient Acceptance of Health Care; Patient Compliance; Recombinant Proteins; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Severity of Illness Index; Substance Abuse, Intravenous; Treatment Outcome	2001
Hepatitis C important treatment advance: interview with Douglas Dieterich, M.D. Interview by John S. James. AIDS treatment news, 1998, May-15, Issue:No 295 Topics: Antiviral Agents; Clinical Trials as Topic; Disease Progression; Drug Therapy, Combination; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Ribavirin; United States; United States Food and Drug Administration	1998
Evolving strategies to attack hepatitis C. GMHC treatment issues : the Gay Men's Health Crisis newsletter of experimental AIDS therapies, 1998, Volume: 12, Issue:12 Topics: Antiviral Agents; Disease Progression; Drug Therapy, Combination; Drugs, Investigational; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin; Risk Factors	1998
Hepatitis C virus and HIV co-infection: a sleeping giant wakes. The Hopkins HIV report : a bimonthly newsletter for healthcare providers, 1999, Volume: 11, Issue:1 Topics: Antiviral Agents; Disease Progression; Drug Therapy, Combination; Drugs, Investigational; Hepatitis C, Chronic; HIV Infections; Humans; Interferon Type I; Polyethylene Glycols; Recombinant Proteins; Ribavirin	1999
Respiratory syncytial virus infections in autologous blood and marrow transplant recipients with breast cancer: combination therapy with aerosolized ribavirin and parenteral immunoglobulins. Bone marrow transplantation, 2001, Volume: 28, Issue:3 Topics: Aerosols; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Bone Marrow Transplantation; Breast Neoplasms; Disease Progression; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulins, Intravenous; Pneumonia, Viral; Respiratory Syncytial Virus Infections; Retrospective Studies; Ribavirin; Survival Rate; Transplantation, Autologous	2001